var title_f20_61_21456="Buccal hyperpigmentation PI";
var content_f20_61_21456=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F56229&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F56229&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Buccal hyperpigmentation due to ACTH excess",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 230px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This photo shows the inner lip of a man with adrenal insufficiency. The lip has darkened areas caused by a hormone imbalance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from: Williams Textbook of Endocrinology, 8th ed, Foster, DW, Wilson, JD (Eds), WB Saunders, Philadelphia, 1996.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_61_21456=[""].join("\n");
var outline_f20_61_21456=null;
var title_f20_61_21457="Margin of pulmonary nodules";
var content_f20_61_21457=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F62360&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F62360&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Margin of pulmonary nodules",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 367px; height: 359px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of different patterns of the margin of pulmonary nodules. In clockwise orientation from top left: smooth, scalloped, corona radiata, and spiculated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_61_21457=[""].join("\n");
var outline_f20_61_21457=null;
var title_f20_61_21458="Borderline lepromatous leprosy";
var content_f20_61_21458=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F52105&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F52105&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Borderline lepromatous leprosy (BL/MB)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 292px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Borderline lepromatous case showing borderline tuberculoid and \"punched- out\" mid borderline lesions together with papular and nodular lesions more typical of lepromatous disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James L Krahenbuhl, PhD and Robert R Jacobson, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_61_21458=[""].join("\n");
var outline_f20_61_21458=null;
var title_f20_61_21459="Tinea versicolor back PI";
var content_f20_61_21459=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F74426&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F74426&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tinea versicolor on the back",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 397px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tinea versicolor can appear as a mixture of colors.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Berg D, Worzala K. Atlas of Adult Physical Diagnosis, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_61_21459=[""].join("\n");
var outline_f20_61_21459=null;
var title_f20_61_21460="Memantine: Patient drug information";
var content_f20_61_21460=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Memantine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/16/24837?source=see_link\">",
"     see \"Memantine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F192478\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Namenda&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F554085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Memantine;",
"     </li>",
"     <li>",
"      CO Memantine;",
"     </li>",
"     <li>",
"      Ebixa&reg;;",
"     </li>",
"     <li>",
"      PMS-Memantine;",
"     </li>",
"     <li>",
"      ratio-Memantine;",
"     </li>",
"     <li>",
"      Riva-Memantine;",
"     </li>",
"     <li>",
"      Sandoz-Memantine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691710",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat Alzheimer's disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691807",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat dementia.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702460",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to memantine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694286",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (solution) if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10014879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10014884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699278",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect liquid (solution) from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11268 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-110.137.129.113-14BEEF5253-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_61_21460=[""].join("\n");
var outline_f20_61_21460=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192478\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F554085\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014876\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014875\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014880\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014881\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014883\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014878\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014879\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014884\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014885\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/16/24837?source=related_link\">",
"      Memantine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_61_21461="Right ventricular cardiac output";
var content_f20_61_21461=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F77775&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F77775&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 606px\">",
"   <div class=\"ttl\">",
"    Right ventricular cardiac output",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 586px; height: 387px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pulse-wave Doppler signal through the pulmonary valve gives a velocity over time, which is integrated to get the velocity time integral (VTI), a measure of right ventricular stroke distance and a proxy for right ventricular cardiac output.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_61_21461=[""].join("\n");
var outline_f20_61_21461=null;
var title_f20_61_21462="Candesartan: Pediatric drug information";
var content_f20_61_21462=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Candesartan: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?37/48/38663?source=see_link\">",
"    see \"Candesartan: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?4/50/4902?source=see_link\">",
"    see \"Candesartan: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F144942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Atacand&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F144943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Candesartan&reg;;",
"     </li>",
"     <li>",
"      Atacand&reg;;",
"     </li>",
"     <li>",
"      CO Candesartan;",
"     </li>",
"     <li>",
"      JAMP-Candesartan;",
"     </li>",
"     <li>",
"      Mylan-Candesartan;",
"     </li>",
"     <li>",
"      PMS-Candesartan;",
"     </li>",
"     <li>",
"      Sandoz-Candesartan;",
"     </li>",
"     <li>",
"      Teva-Candesartan",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1003222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Angiotensin II Receptor Blocker",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihypertensive Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1003254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/48/38663?source=see_link\">",
"      see \"Candesartan: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Use of a lower initial dose is recommended in volume- and salt-depleted patients; dosage must be individualized",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children 1 to &lt;6 years: Oral: Initial: 0.2 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided once or twice daily; titrate to response (within 2 weeks, antihypertensive effect usually observed); usual range: 0.05-0.4 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided once or twice daily; maximum daily dose: 0.4 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     ; higher doses have not been studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children and Adolescents 6 to &lt;17 years: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     &lt;50 kg: Initial: 4-8 mg/",
"     <b>",
"      day",
"     </b>",
"     divided once or twice daily; titrate to response (within 2 weeks, antihypertensive effect usually observed); usual range: 2-16 mg/",
"     <b>",
"      day",
"     </b>",
"     divided once or twice daily; maximum daily dose: 32 mg/",
"     <b>",
"      day",
"     </b>",
"     ; higher doses have not been studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     &gt;50 kg: Initial: 8-16 mg/",
"     <b>",
"      day",
"     </b>",
"     divided once or twice daily; titrate to response (within 2 weeks, antihypertensive effect usually observed); usual range: 4-32 mg/",
"     <b>",
"      day",
"     </b>",
"     divided once or twice daily; maximum daily dose: 32 mg/",
"     <b>",
"      day",
"     </b>",
"     ; higher doses have not been studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adolescents &ge;17 years: Oral: Initial: 16 mg once daily (monotherapy); usual range: 8-32 mg/day divided once or twice daily; blood pressure response is dose-related over the range of 2-32 mg; larger doses do not appear to have a greater effect and there is relatively little experience with such doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Initial: 16 mg once daily (monotherapy); usual range: 8-32 mg/day divided once or twice daily; blood pressure response is dose-related over the range of 2-32 mg; larger doses do not appear to have a greater effect and there is relatively little experience with such doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Congestive heart failure:",
"     </b>",
"     Oral: Initial: 4 mg once daily; double the dose at 2-week intervals, as tolerated; target dose: 32 mg/",
"     <b>",
"      day",
"     </b>",
"     ;",
"     <b>",
"      Note:",
"     </b>",
"     In selected cases, concurrent therapy with an ACE inhibitor may provide additional benefit.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children and Adolescents 1 to &lt;17 years: Not recommended if Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: No initial dosage adjustment necessary; however, in patients with severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute/1.73m",
"     <sup>",
"      2",
"     </sup>",
"     ) AUC and C",
"     <sub>",
"      max",
"     </sub>",
"     were approximately doubled after repeated dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Mild hepatic impairment: No initial dosage adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Moderate hepatic impairment: Consider initiation at lower dosages (AUC increased by 145%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Severe hepatic impairment: There are no dosage adjustments provided in manufacturer&rsquo;s labeling (has not been studied); however, a significant increase in AUC would be expected; consider alternative therapy.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F144918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as cilexetil:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Atacand&reg;: 4 mg, 8 mg, 16 mg, 32 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F144904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13320399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May be administered without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F13319992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 25&ordm;C (77&ordm;F); excursions permitted to 15&ordm;C to 30&ordm;C (59&ordm;F to 86&ordm;F)",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1003223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension alone or in combination with other antihypertensive agents (FDA approved in ages &ge;1 year and adults); treatment of heart failure (NYHA class II-IV) (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7914574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Atacand&reg; may be confused with antacid",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F144982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Angina, hypotension, MI, palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, depression, dizziness, drowsiness, fever, headache, lightheadedness, somnolence, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Angioedema, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperglycemia, hyperkalemia, hypertriglyceridemia, hyperuricemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Dyspepsia, gastroenteritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain, CPK increased, myalgia, paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Hematuria, serum creatinine increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, epistaxis, pharyngitis, rhinitis, upper respiratory tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Rare but important or life-threatening: Abnormal hepatic function, agranulocytosis, anemia, hepatitis, hyponatremia, leukopenia, neutropenia, pruritus, renal failure, renal impairment, thrombocytopenia, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1003228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to candesartan, any component, or other angiotensin II receptor blockers",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F13319911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with hepatic impairment; consider initial dosage adjustment for moderate hepatic impairment. Use with caution in patients with impaired renal function; use is associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure); deterioration may result in oliguria, acute renal failure, or progressive azotemia. Small increases in serum creatinine may occur following initiation; consider discontinuation in patients with progressive and/or significant deterioration in renal function. Hyperkalemia may occur; risk factors include renal dysfunction, diabetes mellitus, concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts; use with caution with these agents; monitor potassium closely. Use caution when initiating in heart failure; may need to adjust dose and/or concurrent diuretic therapy because of candesartan-induced hypotension. Not recommended for use in children &lt;1 year due to possible effects on developing kidneys; has not been studied in children with GFR &lt;30 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     ; use not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1003229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Symptomatic hypotension may occur, especially in patients with an activated renin-angiotensin system (eg, volume- or salt-depleted patients receiving high doses of diuretic agents); use with caution in these patients; correct depletion before starting therapy or initiate therapy at a lower dose. Concomitant use of an ACE inhibitor or renin inhibitor (eg, aliskiren) is associated with an increased risk of hypotension, hyperkalemia, and renal dysfunction. Concomitant use with aliskiren should be avoided in patients with GFR &lt;60 mL/minute and is contraindicated in patients with diabetes mellitus (regardless of GFR).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F144970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C9 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C8 (weak), CYP2C9 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F144913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the hypotensive effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the nephrotoxic effect of Angiotensin II Receptor Blockers. Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Canagliflozin may enhance the hypotensive effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Angiotensin II Receptor Blockers may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an angiotensin II receptor antagonist.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Angiotensin II Receptor Blockers may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with ARBs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1003242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food with high-fat content does not affect AUC. Limit salt substitutes or potassium-rich diet. Avoid natural licorice (causes sodium and water retention and increases potassium loss).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F144914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F144928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"     The use of drugs which act on the renin-angiotensin system are associated with oligohydramnios. Oligohydramnios, due to decreased fetal renal function, may lead to fetal lung hypoplasia and skeletal malformations. Use is also associated with anuria, hypotension, renal failure, skull hypoplasia, and death in the fetus/neonate. The exposed fetus should be monitored for fetal growth, amniotic fluid volume, and organ formation. Infants exposed",
"     <i>",
"      in utero",
"     </i>",
"     should be monitored for hyperkalemia, hypotension, and oliguria.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1003258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, serum creatinine, BUN, baseline and periodic electrolytes",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1003243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Candesartan produces direct antagonism of the effects of angiotensin II. Unlike the ACE inhibitors, candesartan blocks the binding of angiotensin II to the AT1 receptor subtype. It produces its blood pressure-lowering effects by antagonizing AT1-induced vasoconstriction, aldosterone release, catecholamine release, arginine vasopressin release, water intake, and hypertrophic responses. This action results in more efficient blockade of the cardiovascular effects of angiotensin II and fewer side effects than the ACE inhibitors. Candesartan does not affect ACE (kininase II) or the response to bradykinin.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F13320001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensive effect:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Onset of action: Within 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Maximum effect: 4-6 weeks",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1003245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Candesartan: Rapid and complete following conversion from candesartan cilexetil by GI esterases",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.13 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Converted to active candesartan, via ester hydrolysis during absorption from GI tract; hepatic (minor) via O-deethylation to inactive metabolite",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability, absolute: Candesartan: 15%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 9 hours; dose-dependent",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Pediatric patients (1-17 years), adults: 3-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Excreted via biliary and renal routes; feces: 67%; urine: 33% (26% as unchanged drug)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: Total body: 0.37 mL/minute/kg; Renal: 0.19 mL/minute/kg; decreased with severe renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Not removed by hemodialysis",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1003262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/50/4902?source=see_link\">",
"      see \"Candesartan: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not take any new medication (prescription or OTC), herbal products, potassium supplements, or salt substitutes during therapy without consulting prescriber. Take exactly as directed and do not discontinue without consulting prescriber. Medication should be taken at the same time each day; may be taken without regard to meals. This drug does not eliminate need for diet or exercise regimen as recommended by prescriber. May cause dizziness or lightheadedness (use caution when driving or engaging in tasks that require alertness until response to drug is known); or postural hypotension (use caution when rising from lying or sitting position or climbing stairs). Report immediately swelling of face, lips, or mouth; difficulty swallowing; chest pain or palpitations; unrelenting headache; muscle weakness or pain; unusual cough; or other persistent adverse reactions. This medication may cause injury and death to the developing fetus when used during pregnancy; women of childbearing potential should be informed of potential risk; consult prescriber for appropriate contraceptive measures; this medication should be discontinued as soon as possible once pregnancy is detected.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F13333498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral suspension may be made in concentrations ranging from 0.1-2 mg/mL; typically 1 mg/mL oral suspension suitable for majority of prescribed doses; any strength tablet may be used. A 1 mg/mL (total volume: 160 mL) oral suspension may be made with tablets and a 1:1 mixture of Ora-Plus&reg; and Ora-Sweet SF&reg;. Prepare the vehicle by adding 80 mL of Ora-Plus&reg; and 80 mL of Ora-Sweet SF&reg; or, alternatively, use 160 mL of Ora-Blend SF&reg;. Add a small amount of vehicle to five 32 mg tablets and grind into a smooth paste using a mortar and pestle. Transfer the paste to a calibrated amber PET bottle, rinse the mortar and pestle clean using the vehicle, add this to the bottle, and then add a quantity of vehicle sufficient to make 160 mL. The suspension is stable at room temperature for 100 days unopened or 30 days after the first opening; do not freeze; label &ldquo;shake well before use.&rdquo; (Atacand&reg; prescribing information, 2011).",
"    </p>",
"    <div class=\"reference\">",
"     Atacand&reg; prescribing information, AstraZeneca LP, Wilmington, DE, 2011.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Franks AM, O'Brien CE, Stowe CD, et al, \"Candesartan Cilexetil Effectively Reduces Blood Pressure in Hypertensive Children,\"",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2008, 42(10):1388-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/61/21462/abstract-text/18664605/pubmed\" id=\"18664605\" target=\"_blank\">",
"        18664605",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hoy SM and Keating GM, \"Candesartan Cilexetil: In Children and Adolescents Aged 1 to &lt;17 Years With Hypertension,\"",
"      <i>",
"       Am J Cardiovasc Drugs",
"      </i>",
"      , 2010, 10(5):335-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/61/21462/abstract-text/20860416/pubmed\" id=\"20860416\" target=\"_blank\">",
"        20860416",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schaefer F, van de Walle J, Zurowska A, et al, \"Efficacy, Safety and Pharmacokinetics of Candesartan Cilexetil in Hypertensive Children From 1 to Less Than 6 Years of Age,\"",
"      <i>",
"       J Hypertens",
"      </i>",
"      , 2010, 28(5):1083-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/61/21462/abstract-text/20160654/pubmed\" id=\"20160654\" target=\"_blank\">",
"        20160654",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trachtman H, Hainer JW, Sugg J, et al, \"Efficacy, Safety, and Pharmacokinetics of Candesartan Cilexetil in Hypertensive Children Aged 6 to 17 Years,\"",
"      <i>",
"       J Clin Hypertens (Greenwich)",
"      </i>",
"      , 2008, 10(10):743-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/61/21462/abstract-text/19090875/pubmed\" id=\"19090875\" target=\"_blank\">",
"        19090875",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17058 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-89.32.226.102-7D0333FE40-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_61_21462=[""].join("\n");
var outline_f20_61_21462=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708657\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144942\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144943\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1003222\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1003254\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144918\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144904\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13320399\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13319992\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1003223\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7914574\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144982\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1003228\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13319911\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1003229\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144970\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144913\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1003242\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144914\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144928\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1003258\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1003243\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13320001\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1003245\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1003262\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13333498\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/17058\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/17058|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/48/38663?source=related_link\">",
"      Candesartan: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/50/4902?source=related_link\">",
"      Candesartan: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_61_21463="Rheumatoid arthritis symptoms and diagnosis";
var content_f20_61_21463=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"topicTitle\">",
"   Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/61/21463/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/61/21463/contributors\">",
"     RN Maini, BA, MB BChir, FRCP, FMedSci, FRS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/61/21463/contributors\">",
"     PJW Venables, MA, MB BChir, MD, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/61/21463/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/61/21463/contributors\">",
"     James R O'Dell, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/61/21463/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/61/21463/contributors\">",
"     Jerry M Greene, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/61/21463/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     RHEUMATOID ARTHRITIS OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rheumatoid arthritis is a chronic inflammatory condition. Rheumatoid arthritis symptoms develop gradually and may include joint pain, stiffness, and swelling. The condition can affect many tissues throughout the body, but the joints are usually most severely affected. The cause of rheumatoid arthritis is unknown.",
"   </p>",
"   <p>",
"    This article discusses the risk factors, symptoms, and evaluation of rheumatoid arthritis. A number of other articles about rheumatoid arthritis are also available. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?23/44/24264?source=see_link\">",
"     \"Patient information: Rheumatoid arthritis treatment (Beyond the Basics)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?26/40/27266?source=see_link\">",
"     \"Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?11/52/12098?source=see_link\">",
"     \"Patient information: Rheumatoid arthritis and pregnancy (Beyond the Basics)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?38/29/39378?source=see_link\">",
"     \"Patient information: Complementary therapies for rheumatoid arthritis (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RHEUMATOID ARTHRITIS RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The specific cause of rheumatoid arthritis is not known. Researchers suspect that two types of factors affect a person's risk: susceptibility factors and initiating factors.",
"   </p>",
"   <p>",
"    Rheumatoid arthritis most likely occurs when a susceptible person is exposed to factors that start the inflammatory process. Approximately 1 in every 100 individuals has rheumatoid arthritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/42/39593?source=see_link\">",
"     \"Epidemiology of, risk factors for, and possible causes of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gender, heredity, and genes largely determine a person's risk of developing rheumatoid arthritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Gender",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gender appears to play a major role in a person's susceptibility to rheumatoid arthritis. Women are about three times more likely than men to develop rheumatoid arthritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Heredity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rheumatoid arthritis is not an inherited disease. Genes do not cause rheumatoid arthritis; they merely affect the risk of its development.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Specific genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;People with specific variants of human leukocyte antigen (HLA) genes are more likely to develop rheumatoid arthritis than people with other gene variants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Initiating factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many individuals who carry HLA genes never develop the condition. Indeed, when one identical twin has rheumatoid arthritis, the chance that the other will develop disease is only about 1 in 3. This suggests that additional factors must be necessary for a person to develop RA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Researchers suspect that infection with bacteria or viruses may be one of the factors that initiate rheumatoid arthritis. However, at this time, there is no definite evidence linking infection to rheumatoid arthritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Cigarette smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cigarette smoking may increase the risk of developing rheumatoid arthritis. There is also some evidence that cigarette smoking increases the likelihood that rheumatoid arthritis will be severe when it occurs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Stress",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients often report episodes of stress or trauma preceding the onset of their rheumatoid arthritis. Stressful &ldquo;life events&rdquo; (eg, divorce, accidents, grief, etc.) are more common in people with RA in the six months before their diagnosis compared with the general population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     RHEUMATOID ARTHRITIS SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most people, rheumatoid arthritis begins insidiously, and weeks or months may pass before the characteristic symptoms are bothersome enough to cause a person to seek medical care. Early symptoms may include fatigue, muscle pain, a low-grade fever, weight loss, and numbness and tingling in the hands. In some cases, these symptoms occur before joint pain or stiffness is noticeable. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=see_link\">",
"     \"Clinical features of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Occasionally, rheumatoid arthritis begins with symptoms related to inflammation of tissues other than the joints. For example, a person may experience chest pain or shortness of breath.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pattern of joints affected",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rheumatoid arthritis usually affects the same joints on both sides of the body.",
"   </p>",
"   <p>",
"    In the early stages, rheumatoid arthritis typically affects small joints, especially the joints at the base of the fingers, the joints in the middle of the fingers, and the joints at the base of the toes. It may also begin in a single, large joint, such as the knee or shoulder, or it may come and go and move from one joint to another.",
"   </p>",
"   <p>",
"    As the condition progresses, most people have inflammation of the joints in the arms or legs, and between 20 and 50 percent of people have inflammation of the large central joints (eg, hips) and spine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Joint symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The joint symptoms of rheumatoid arthritis usually begin gradually and include pain, stiffness, redness, warmth to the touch, and joint swelling.",
"   </p>",
"   <p>",
"    The joint stiffness is most bothersome in the morning and after sitting still for a period of time. The stiffness can persist for more than one hour.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hands &mdash; The joints of the hands are often the very first joints affected by rheumatoid arthritis. These joints are tender when squeezed, and the hand's grip strength is often reduced. Occasionally, rheumatoid arthritis may lead to visible redness and swelling of the entire hand.",
"      <br/>",
"      <br/>",
"      Between 1 and 5 percent of people with rheumatoid arthritis develop carpal tunnel syndrome because swelling compresses a nerve that runs through the wrist; this syndrome is characterized by weakness, tingling, and numbness of certain areas of the hand.",
"      <br/>",
"      <br/>",
"      Certain characteristic hand deformities can occur with long-standing rheumatoid arthritis. The fingers may develop characteristic, exaggerated profiles, called swan neck deformities (",
"      <a class=\"graphic graphic_picture graphicRef70434 \" href=\"UTD.htm?31/5/31828\">",
"       picture 1",
"      </a>",
"      ) and boutonniere deformities, and they may drift together in the direction of the small finger. The tendons on the back of the hand may become very prominent and tight, which is called the bow string sign.",
"     </li>",
"     <li>",
"      Wrist &mdash; The wrist is the most commonly affected joint of the arm in people with rheumatoid arthritis. In the early stages of rheumatoid arthritis, it may become difficult to bend the wrist backward.",
"     </li>",
"     <li>",
"      Elbow &mdash; Rheumatoid arthritis may cause inflammation of the elbow. Swelling of this joint may compress nerves that travel through the arm and may cause numbness or tingling in the fingers.",
"     </li>",
"     <li>",
"      Shoulder &mdash; The shoulder may be inflamed in the later stages of rheumatoid arthritis, causing pain and limited motion.",
"     </li>",
"     <li>",
"      Foot &mdash; The joints of the feet are often affected in the early stages of rheumatoid arthritis, especially the joints at the base of the toes. Tenderness at these joints may cause a person to stand and walk with his or her weight on the heels, with the toes bent upward. The top of the foot may be swollen and red, and, occasionally, the heel may be painful.",
"     </li>",
"     <li>",
"      Ankle &mdash; Rheumatoid arthritis may cause inflammation of the ankle. Inflammation of this joint may cause nerve damage, leading to numbness and tingling in the foot.",
"     </li>",
"     <li>",
"      Knee &mdash; Rheumatoid arthritis may cause swelling of the knee, difficulty bending the knee, excessive looseness of the ligaments that surround and support the knee, and damage of the ends of the bones that meet at the knee. Rheumatoid arthritis may also cause the formation of a Baker's cyst (a cyst filled with joint fluid and located in the hollow space at the back of the knee).",
"     </li>",
"     <li>",
"      Hips &mdash; The hips may become inflamed in the later stages of rheumatoid arthritis. Pain in the hips may make it difficult to walk.",
"     </li>",
"     <li>",
"      Cervical spine &mdash; Rheumatoid arthritis may cause inflammation of the cervical spine, which is the area between the shoulders and the base of the head. Inflammation of the cervical spine may cause a painful and stiff neck and a decreased ability to bend the neck and turn the head.",
"     </li>",
"     <li>",
"      Cricoarytenoid joint &mdash; In about 30 percent of people with rheumatoid arthritis, there is inflammation of a joint near the windpipe called the cricoarytenoid joint. Inflammation of this joint can cause hoarseness and difficulty breathing.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Other symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although joint problems are the most commonly known issues in rheumatoid arthritis, the condition can be associated with a variety of other problems.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Rheumatoid nodules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rheumatoid nodules are painless lumps that appear beneath the skin. These nodules may move easily when touched, or they may be fixed to deeper tissues. They most often occur on the underside of the forearm and on the elbow, but they can also occur on other pressure points, including the back of the head, the base of the spine, the Achilles tendon, and the tendons of the hand.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Inflammatory conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rheumatoid arthritis may produce a variety of other symptoms, depending on which tissues are inflamed.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inflammation of the tissue lining the chest cavity and surrounding the heart may cause chest pain and difficulty breathing. (See",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/53/12115?source=see_link\">",
"       \"Patient information: Pericarditis (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Inflammation of the lung that is not due to infection may cause shortness of breath and a dry cough.",
"     </li>",
"     <li>",
"      Abnormal nerve function may cause numbness, tingling, or weakness.",
"     </li>",
"     <li>",
"      Inflammation of the white part of the eye may cause pain or vision problems.",
"     </li>",
"     <li>",
"      Enlargement of the spleen may cause a fall in the number of white blood cells, which may lead to infections.",
"     </li>",
"     <li>",
"      Sj&ouml;gren's syndrome causes dry eyes and dry mouth, which can lead to a gritty feeling or a sensation of irritating material in the eyes. Mouth dryness may make it difficult to chew or swallow without drinking something at the same time. Women may develop vaginal dryness due to Sj&ouml;gren's syndrome, leading to pain with sexual intercourse. (See",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/11/44212?source=see_link\">",
"       \"Patient information: Sj&ouml;gren&rsquo;s syndrome (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Vasculitis (inflammation of the blood vessels) may cause a wide variety of symptoms, depending upon where the inflamed blood vessels are located. (See",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/22/44389?source=see_link\">",
"       \"Patient information: Vasculitis (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     RHEUMATOID ARTHRITIS DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no single test used to diagnose rheumatoid arthritis. Instead, the diagnosis is based upon many factors, including the characteristic signs and symptoms, the results of laboratory tests, and the results of x-rays. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6010?source=see_link\">",
"     \"Diagnosis and differential diagnosis of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A person with well-established rheumatoid arthritis typically has or has had at least several of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Morning stiffness that lasts at least one hour and that has been present for at least six weeks",
"     </li>",
"     <li>",
"      Swelling of three or more joints for at least six weeks",
"     </li>",
"     <li>",
"      Swelling of the wrist, hand, or finger joints for at least six weeks",
"     </li>",
"     <li>",
"      Swelling of the same joints on both sides of the body",
"     </li>",
"     <li>",
"      Changes in hand x-rays that are characteristic of rheumatoid arthritis",
"     </li>",
"     <li>",
"      Rheumatoid nodules of the skin",
"     </li>",
"     <li>",
"      Blood test positive for rheumatoid factor",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      anti-citrullinated",
"      <span class=\"nowrap\">",
"       peptide/protein",
"      </span>",
"      antibodies",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Not all of these features are present in people with early RA, and these problems may be present in some people with other rheumatic conditions.",
"   </p>",
"   <p>",
"    In some cases, it may be necessary to monitor the condition over time before a diagnosis of rheumatoid arthritis can be made with certainty.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory tests help to confirm the presence of rheumatoid arthritis, to differentiate it from other conditions, and to predict the likely course of the condition and its response to treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Rheumatoid factor (RF)",
"    </span>",
"    &nbsp;&mdash;&nbsp;An antibody called rheumatoid factor is present in the blood of 70 to 80 percent of people with rheumatoid arthritis. However, rheumatoid factor is also found in people with other types of rheumatic disease and in a small number of healthy individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Anti-citrullinated peptide/protein antibody test",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood tests for antibodies to citrullinated",
"    <span class=\"nowrap\">",
"     peptides/proteins",
"    </span>",
"    (ACPA) are more specific than rheumatoid factor for diagnosing rheumatoid arthritis. Anti-ACPA antibody tests may be positive very early in the course of disease. The test is positive in most patients with rheumatoid arthritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     RHEUMATOID ARTHRITIS TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A separate article discusses rheumatoid arthritis treatment. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?23/44/24264?source=see_link\">",
"     \"Patient information: Rheumatoid arthritis treatment (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     RHEUMATOID ARTHRITIS DISEASE COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rheumatoid arthritis often has a variable course: it can go into remission, follow a fluctuating course, or worsen steadily. In most people with rheumatoid arthritis, the severity of symptoms fluctuates for weeks or months. It is generally impossible to predict how the disease will affect a particular individual. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/11/184?source=see_link\">",
"     \"Disease outcome and functional capacity in rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment can drive the condition into remission, although remission is rare without treatment. In about 10 to 20 percent of people, rheumatoid arthritis progresses steadily despite treatment. Remission in pregnancy is common, although greater than 90 percent of women have a flare of arthritis symptoms within three months after childbirth. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?11/52/12098?source=see_link\">",
"     \"Patient information: Rheumatoid arthritis and pregnancy (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Long-term effects of rheumatoid arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inflammation of rheumatoid arthritis can potentially damage the bones, cartilage, and other structures of the joints. The joint damage typically worsens over time and is irreversible.",
"   </p>",
"   <p>",
"    The risk of these problems and the risk of joint damage and disability can be reduced when early and effective disease-modifying treatments are used. Treatment is strongly recommended as soon a person is diagnosed with rheumatoid arthritis, even in those who have not yet developed x-ray changes. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?23/44/24264?source=see_link\">",
"     \"Patient information: Rheumatoid arthritis treatment (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     WHERE TO GET MORE INFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"   </p>",
"   <p>",
"    This article will be updated as needed on our web site (",
"    <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"     www.uptodate.com/patients",
"    </a>",
"    ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3498531815\">",
"    <span class=\"h2\">",
"     Patient level information",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1944727\">",
"    <span class=\"h3\">",
"     The Basics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?16/31/16883?source=see_link\">",
"     Patient information: Rheumatoid arthritis (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?38/14/39138?source=see_link\">",
"     Patient information: Rheumatoid arthritis and pregnancy (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?7/11/7347?source=see_link\">",
"     Patient information: Hand pain (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?0/21/338?source=see_link\">",
"     Patient information: Ganglion cyst (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?28/28/29122?source=see_link\">",
"     Patient information: Pyoderma gangrenosum (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?30/8/30850?source=see_link\">",
"     Patient information: Antinuclear antibodies (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?14/9/14483?source=see_link\">",
"     Patient information: Interstitial lung disease (The Basics)",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1944744\">",
"    <span class=\"h3\">",
"     Beyond the Basics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?23/44/24264?source=see_link\">",
"     Patient information: Rheumatoid arthritis treatment (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?26/40/27266?source=see_link\">",
"     Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?11/52/12098?source=see_link\">",
"     Patient information: Rheumatoid arthritis and pregnancy (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?38/29/39378?source=see_link\">",
"     Patient information: Complementary therapies for rheumatoid arthritis (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?11/53/12115?source=see_link\">",
"     Patient information: Pericarditis (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?43/11/44212?source=see_link\">",
"     Patient information: Sj&ouml;gren&rsquo;s syndrome (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?43/22/44389?source=see_link\">",
"     Patient information: Vasculitis (Beyond the Basics)",
"    </a>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Professional level information",
"    </span>",
"    &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/33/7706?source=see_link\">",
"     Assessment of rheumatoid arthritis activity in clinical trials and clinical practice",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41080?source=see_link\">",
"     Cervical subluxation in rheumatoid arthritis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=see_link\">",
"     Clinical features of rheumatoid arthritis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/25/24983?source=see_link\">",
"     Polyarticular onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33528?source=see_link\">",
"     Clinically useful biologic markers in the diagnosis and assessment of outcome in rheumatoid arthritis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6010?source=see_link\">",
"     Diagnosis and differential diagnosis of rheumatoid arthritis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/11/184?source=see_link\">",
"     Disease outcome and functional capacity in rheumatoid arthritis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/42/39593?source=see_link\">",
"     Epidemiology of, risk factors for, and possible causes of rheumatoid arthritis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37861?source=see_link\">",
"     Evaluation and medical management of end-stage rheumatoid arthritis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=see_link\">",
"     General principles of management of rheumatoid arthritis in adults",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/31/17912?source=see_link\">",
"     Interstitial lung disease in rheumatoid arthritis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/59/10169?source=see_link\">",
"     Leflunomide in the treatment of rheumatoid arthritis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/48/17162?source=see_link\">",
"     Polyarticular onset juvenile idiopathic arthritis: Management",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/35/566?source=see_link\">",
"     Miscellaneous novel therapies in rheumatoid arthritis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22903?source=see_link\">",
"     Ocular manifestations of rheumatoid arthritis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18954?source=see_link\">",
"     Overview of the systemic and nonarticular manifestations of rheumatoid arthritis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35016?source=see_link\">",
"     Randomized clinical trials in rheumatoid arthritis of biologic agents that inhibit IL-1, IL-6, and RANKL",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/53/40791?source=see_link\">",
"     Rheumatoid arthritis and pregnancy",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21130?source=see_link\">",
"     Rituximab and other B cell targeted therapies for rheumatoid arthritis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/27/2490?source=see_link\">",
"     Sulfasalazine in the treatment of rheumatoid arthritis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/0/9223?source=see_link\">",
"     T cell targeted therapies for rheumatoid arthritis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/20/32073?source=see_link\">",
"     Total joint replacement for severe rheumatoid arthritis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/1/15385?source=see_link\">",
"     Initial treatment of mildly active rheumatoid arthritis in adults",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/3/31802?source=see_link\">",
"     Initial treatment of moderately to severely active rheumatoid arthritis in adults",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/6/42090?source=see_link\">",
"     Treatment of rheumatoid arthritis resistant to initial DMARD therapy in adults",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41065?source=see_link\">",
"     Use of glucocorticoids in the treatment of rheumatoid arthritis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=see_link\">",
"     Use of methotrexate in the treatment of rheumatoid arthritis",
"    </a>",
"    <br/>",
"   </p>",
"   <p>",
"    The following organizations also provide reliable health information.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      National Library of Medicine",
"      <br/>",
"      (",
"      <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/arthritis.html\">",
"       www.nlm.nih.gov/medlineplus/arthritis.html",
"      </a>",
"      , available in Spanish)",
"     </li>",
"     <li>",
"      National Institute of Arthritis and Musculoskeletal and Skin Diseases",
"      <br/>",
"      (301) 496-8188",
"      <br/>",
"      (",
"      <a class=\"external\" href=\"file://www.niams.nih.gov/Health_Info/Arthritis/default.asp\">",
"       www.niams.nih.gov/Health_Info/Arthritis/default.asp",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      National Institute on Aging",
"      <br/>",
"      (",
"      <a class=\"external\" href=\"file://www.nia.nih.gov/health/publication/arthritis-advice\">",
"       www.nia.nih.gov/health/publication/arthritis-advice",
"      </a>",
"      , available in Spanish)",
"     </li>",
"     <li>",
"      American College of Rheumatology",
"      <br/>",
"      (404) 633-3777",
"      <br/>",
"      (",
"      <a class=\"external\" href=\"file://www.rheumatology.org/\">",
"       www.rheumatology.org",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The Arthritis Foundation",
"      <br/>",
"      (800) 283-7800",
"      <br/>",
"      (",
"      <a class=\"external\" href=\"file://www.arthritis.org/\">",
"       www.arthritis.org",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Patient Support",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of online forums where patients can find information and support from other people with similar conditions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"external\" href=\"file://about.com/\">",
"       About.com",
"      </a>",
"      Arthritis Forum",
"      <br/>",
"      (",
"      <a class=\"external\" href=\"file://arthritis.about.com/forum\">",
"       file://arthritis.about.com/forum",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21463/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21463/abstract/1\">",
"      Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001; 358:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21463/abstract/2\">",
"      Aletaha D, Ward MM, Machold KP, et al. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum 2005; 52:2625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21463/abstract/3\">",
"      van der Heijde D, Klareskog L, Boers M, et al. Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. Ann Rheum Dis 2005; 64:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21463/abstract/4\">",
"      Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 512 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-190.92.87.104-FFAD13B8AB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_61_21463=[""].join("\n");
var outline_f20_61_21463=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      RHEUMATOID ARTHRITIS OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RHEUMATOID ARTHRITIS RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Gender",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Heredity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Specific genes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Initiating factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Cigarette smoking",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Stress",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      RHEUMATOID ARTHRITIS SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pattern of joints affected",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Joint symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Other symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Rheumatoid nodules",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Inflammatory conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      RHEUMATOID ARTHRITIS DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Rheumatoid factor (RF)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Anti-citrullinated peptide/protein antibody test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      RHEUMATOID ARTHRITIS TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      RHEUMATOID ARTHRITIS DISEASE COURSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Long-term effects of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      WHERE TO GET MORE INFORMATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3498531815\">",
"      Patient level information",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1944727\">",
"      - The Basics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1944744\">",
"      - Beyond the Basics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Professional level information",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Patient Support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/512\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PI/512|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/5/31828\" title=\"picture 1\">",
"      Hands in RA PI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/33/7706?source=related_link\">",
"      Assessment of rheumatoid arthritis activity in clinical trials and clinical practice",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41080?source=related_link\">",
"      Cervical subluxation in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=related_link\">",
"      Clinical features of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33528?source=related_link\">",
"      Clinically useful biologic markers in the diagnosis and assessment of outcome in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6010?source=related_link\">",
"      Diagnosis and differential diagnosis of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/11/184?source=related_link\">",
"      Disease outcome and functional capacity in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/42/39593?source=related_link\">",
"      Epidemiology of, risk factors for, and possible causes of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37861?source=related_link\">",
"      Evaluation and medical management of end-stage rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=related_link\">",
"      General principles of management of rheumatoid arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/1/15385?source=related_link\">",
"      Initial treatment of mildly active rheumatoid arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/3/31802?source=related_link\">",
"      Initial treatment of moderately to severely active rheumatoid arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/31/17912?source=related_link\">",
"      Interstitial lung disease in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/59/10169?source=related_link\">",
"      Leflunomide in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/35/566?source=related_link\">",
"      Miscellaneous novel therapies in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22903?source=related_link\">",
"      Ocular manifestations of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18954?source=related_link\">",
"      Overview of the systemic and nonarticular manifestations of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/8/30850?source=related_link\">",
"      Patient information: Antinuclear antibodies (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/29/39378?source=related_link\">",
"      Patient information: Complementary therapies for rheumatoid arthritis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/40/27266?source=related_link\">",
"      Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/21/338?source=related_link\">",
"      Patient information: Ganglion cyst (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/11/7347?source=related_link\">",
"      Patient information: Hand pain (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/9/14483?source=related_link\">",
"      Patient information: Interstitial lung disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/53/12115?source=related_link\">",
"      Patient information: Pericarditis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/28/29122?source=related_link\">",
"      Patient information: Pyoderma gangrenosum (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/31/16883?source=related_link\">",
"      Patient information: Rheumatoid arthritis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/52/12098?source=related_link\">",
"      Patient information: Rheumatoid arthritis and pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/14/39138?source=related_link\">",
"      Patient information: Rheumatoid arthritis and pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/44/24264?source=related_link\">",
"      Patient information: Rheumatoid arthritis treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/11/44212?source=related_link\">",
"      Patient information: Sj&ouml;gren&rsquo;s syndrome (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/22/44389?source=related_link\">",
"      Patient information: Vasculitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/25/24983?source=related_link\">",
"      Polyarticular onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/48/17162?source=related_link\">",
"      Polyarticular onset juvenile idiopathic arthritis: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35016?source=related_link\">",
"      Randomized clinical trials in rheumatoid arthritis of biologic agents that inhibit IL-1, IL-6, and RANKL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/53/40791?source=related_link\">",
"      Rheumatoid arthritis and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21130?source=related_link\">",
"      Rituximab and other B cell targeted therapies for rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/27/2490?source=related_link\">",
"      Sulfasalazine in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/0/9223?source=related_link\">",
"      T cell targeted therapies for rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/20/32073?source=related_link\">",
"      Total joint replacement for severe rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/6/42090?source=related_link\">",
"      Treatment of rheumatoid arthritis resistant to initial DMARD therapy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41065?source=related_link\">",
"      Use of glucocorticoids in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=related_link\">",
"      Use of methotrexate in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_61_21464="Assessment of stridor in children";
var content_f20_61_21464=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Assessment of stridor in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/61/21464/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/61/21464/contributors\">",
"     Diana R Quintero, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/61/21464/contributors\">",
"     Khoulood Fakhoury, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/61/21464/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/61/21464/contributors\">",
"     Gregory Redding, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/61/21464/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/61/21464/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/61/21464/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An examination of the etymology of the English word stridor indicates that the noun is derived from the Latin verb",
"    <em>",
"     stridere",
"    </em>",
"    , meaning to make a harsh noise or shrill sound, as to creak. Appropriately, one of the primary uses of the word stridor, today, is to signify a high-pitched, musical sound made when breathing, which is usually superimposed on the normal breath sounds. Stridor is caused by the oscillation of a narrowed airway, and its presence suggests significant obstruction of the large airways. The acoustics of stridor may be explained as a result of Bernoulli's Principle, which states that as the speed of a moving fluid increases, the pressure within the fluid decreases. In an application in which airflow is forced through a narrowed tube, a local area of low pressure creates a vacuum effect distal to the narrowing. The focal area of low pressure distal to a narrowed airway causes the airway walls to collapse and vibrate, generating the squeak characteristic of stridor [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21464/abstract/1-5\">",
"     1-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A commonly encountered presenting symptom in the pediatric population, stridor is an important physical finding that requires prompt evaluation. The pathophysiology, differential diagnosis and clinical management of stridor will be reviewed here. Other common presenting respiratory symptoms, including wheeze and cough, are presented separately, as is the emergent evaluation and treatment of acute upper airway obstruction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30424?source=see_link\">",
"     \"Approach to wheezing in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/41/1689?source=see_link\">",
"     \"Wheezing illnesses other than asthma in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/9/17561?source=see_link\">",
"     \"Approach to chronic cough in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/61/10201?source=see_link\">",
"     \"Emergent evaluation of acute upper airway obstruction in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY AND ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anatomically, the upper airway can be divided into two regions, extrathoracic and intrathoracic:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Extrathoracic",
"    </span>",
"    &nbsp;&mdash;&nbsp;This region includes airways above the thoracic inlet, which, in turn, can be subdivided into two anatomic areas:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Supraglottic area",
"    </span>",
"    &nbsp;&mdash;&nbsp;This area includes the nasopharynx, epiglottis, larynx, aryepiglottic folds, and false vocal cords. The walls supporting this region are made of soft tissue and muscles, and lack cartilaginous support. Therefore, airway collapse and obstruction can occur easily and progress rapidly in this area.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Glottic and subglottic area",
"    </span>",
"    &nbsp;&mdash;&nbsp;This portion of the airway extends from the vocal cords to the extrathoracic segment of the trachea, just before it enters the thoracic cavity. The glottic area has some cartilaginous support (ie, cricoid cartilage and incomplete tracheal rings), which makes it less vulnerable to collapse than the supraglottic area. The subglottis, surrounded by the cricoid cartilage, is the narrowest part of the trachea, with a diameter of 5 to 7 mm at birth. A narrowing by 1 mm in the subglottic area will decrease the cross-sectional area by 75 percent and increase airway resistance 16 fold [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21464/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Classic diseases that cause acute obstruction at extrathoracic level include laryngotracheitis (croup), epiglottitis, retropharyngeal abscess, and diphtheria [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21464/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43529?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical features, evaluation, and diagnosis of croup\", section on 'Clinical presentation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/45/4826?source=see_link\">",
"     \"Epiglottitis (supraglottitis): Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43992?source=see_link\">",
"     \"Retropharyngeal infections in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/38/29287?source=see_link\">",
"     \"Epidemiology, pathophysiology and clinical manifestations of diphtheria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Laryngomalacia is the most common cause of chronic extrathoracic airway obstruction in infants [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21464/abstract/6\">",
"     6",
"    </a>",
"    ]. However, other abnormalities can also result in obstruction at this level, including tracheomalacia, vocal cord paralysis, and subglottic stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21464/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/42/37543?source=see_link&amp;anchor=H3#H3\">",
"     \"Congenital anomalies of the larynx\", section on 'Laryngomalacia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/42/37543?source=see_link&amp;anchor=H12#H12\">",
"     \"Congenital anomalies of the larynx\", section on 'Atresia and stenosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29114?source=see_link&amp;anchor=H11#H11\">",
"     \"Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula\", section on 'Tracheomalacia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/29/44505?source=see_link&amp;anchor=H7#H7\">",
"     \"Etiology and management of hoarseness in children\", section on 'Vocal fold paralysis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Intrathoracic",
"    </span>",
"    &nbsp;&mdash;&nbsp;This includes the portion of the trachea that lies within the thoracic cavity, as well as the mainstem bronchi. Although compression of the proximal trachea can result in expiratory stridor, intrathoracic airway compression usually gives rise to wheezing. Congenital disorders are a prominent cause of obstruction at this level (eg, vascular rings and webs) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21464/abstract/7\">",
"     7",
"    </a>",
"    ]. Foreign bodies and compression by an enlarged lymph nodes or tumors can also occur at this level [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21464/abstract/1,8\">",
"     1,8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/5/27735?source=see_link\">",
"     \"Vascular rings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;During inspiration with the mouth open, air flows in because the intrathoracic pressure is lower than the atmospheric pressure. During expiration, the pressure inside the rib cage increases above the atmospheric pressure, allowing air to flow out. In normal individuals, during inspiration, the extrathoracic pressure is equal to the atmospheric pressure and exceeds the intratracheal pressure, producing some collapse of the airway, which is not clinically relevant. However, in the presence of a non-rigid extrathoracic obstruction, the increased Bernoulli effect results in a more profound drop in the airway pressure distal to the obstruction. This leads to the collapse of the airway walls and to an increase in the obstruction; this in turn limits the airflow and causes turbulence, thus producing inspiratory stridor (",
"    <a class=\"graphic graphic_figure graphicRef65386 \" href=\"UTD.htm?17/3/17470\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Stridor originating from the extrathoracic area is more pronounced during inspiration, and tends to abate during exhalation. Stridor caused by obstruction at the glottis (vocal cords) may occur during inspiration only, or during both inspiration and expiration, since the shape and size of this part of the airway change little during the process of respiration.",
"   </p>",
"   <p>",
"    If airway narrowing originates from the nasal, nasopharyngeal or oropharyngeal areas, the noise generated is typically of low pitch character and referred to as snoring or stertor.",
"   </p>",
"   <p>",
"    Stridor that originates in the intrathoracic airways is usually more pronounced on exhalation, since intrathoracic pressure rises on expiration and causes airway collapse. During inspiration, intrathoracic pressure falls and the airways are more open with lessening of obstruction, leading to a quieter sound (",
"    <a class=\"graphic graphic_figure graphicRef55931 \" href=\"UTD.htm?14/54/15214\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    If the obstruction at any level is critical and fixed, it can result in biphasic inspiratory and expiratory stridor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stridor may result from a variety of conditions that can be either congenital or acquired (",
"    <a class=\"graphic graphic_table graphicRef62718 graphicRef71405 \" href=\"UTD.htm?5/6/5230\">",
"     table 1A-B",
"    </a>",
"    ). A thorough clinical history and a complete physical examination are major components in reaching the diagnosis. In some cases, additional diagnostic testing, including radiography, pulmonary function testing, and even airway visualization, may be required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several historical details can aid in diagnosis:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Age of onset is an important determinant that can help identify the cause of stridor. Generally, congenital disorders (eg, laryngomalacia, subglottic stenosis and tracheomalacia) present in the first few weeks of life. However, some congenital defects such as bronchogenic cysts and laryngeal clefts may also manifest later in infancy or toddler years and should be considered in the differential diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21464/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/42/37543?source=see_link\">",
"     \"Congenital anomalies of the larynx\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29114?source=see_link&amp;anchor=H11#H11\">",
"     \"Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula\", section on 'Tracheomalacia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29114?source=see_link&amp;anchor=H29#H29\">",
"     \"Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula\", section on 'Bronchogenic cyst'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Foreign body aspiration is more commonly seen above six months of age, when the child becomes able to reach for things and to grab small objects, with incidence peaking around two to three years of age. In one study, 85 percent of children with foreign body aspiration were found to be less than three years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21464/abstract/12\">",
"     12",
"    </a>",
"    ]. If the child is in an environment with older children, foreign body aspiration can occur at an earlier age. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2585?source=see_link\">",
"     \"Airway foreign bodies in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Croup most commonly occurs in children 6 to 36 months of age. It is seen in younger infants (as young as three months) and in preschool children, but is rare beyond age six years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43529?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical features, evaluation, and diagnosis of croup\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most retropharyngeal abscesses occur in children less than four years of age. In the past, epiglottitis commonly occurred between two and seven years of age. Since the introduction of the H. influenzae type B vaccine, the incidence of epiglottitis has dropped dramatically; the peak age for epiglottitis is now greater than seven years [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21464/abstract/13\">",
"     13",
"    </a>",
"    ]. However, epiglottitis can occur at any age. Peritonsillar abscess is another cause of stridor and airway obstruction in children. Its incidence peaks in children older than 10 years of age, when streptococcal pharyngitis becomes more common. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43992?source=see_link\">",
"     \"Retropharyngeal infections in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/45/4826?source=see_link\">",
"     \"Epiglottitis (supraglottitis): Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41417?source=see_link&amp;anchor=H4#H4\">",
"     \"Approach to diagnosis of acute infectious pharyngitis in children and adolescents\", section on 'Group A streptococcus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most of the other causes of stridor can occur at any age, so other clues in the history should be elicited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Acuity of onset and severity",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to determine the acuity of onset and the severity of the symptom. Foreign body aspiration should always be suspected in a toddler who presents with sudden onset of stridor, with or without respiratory distress, and without other physical findings. Severe allergic reactions (anaphylaxis and laryngeal edema) can present with abrupt, severe onset and require rapid intervention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2585?source=see_link\">",
"     \"Airway foreign bodies in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Abrupt onset of stridor, fever, and hoarseness, accompanied by other upper respiratory symptoms, suggests an infectious process. It is important to note the timeframe and severity of symptoms, since serious bacterial infections can present with rapidly progressive respiratory distress, drooling, and gasping for air. These findings, which suggest a critically narrowed airway, signify an emergency requiring prompt medical attention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/61/10201?source=see_link&amp;anchor=H4#H4\">",
"     \"Emergent evaluation of acute upper airway obstruction in children\", section on 'Infectious etiologies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/45/4826?source=see_link\">",
"     \"Epiglottitis (supraglottitis): Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bacterial tracheitis is becoming a more common cause of respiratory failure than viral croup and epiglottitis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21464/abstract/14\">",
"     14",
"    </a>",
"    ]. Bacterial tracheitis should be considered in children who present with acute life-threatening upper airway infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32536?source=see_link&amp;anchor=H8#H8\">",
"     \"Bacterial tracheitis in children: Clinical features and diagnosis\", section on 'Presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Viral croup usually presents in a more insidious way, with steady, progressive respiratory distress, and usually improves within a few days to a week. It accounts for more than 90 percent of all cases of stridor in children [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21464/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43529?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical features, evaluation, and diagnosis of croup\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Delayed airway burns should always be considered in any child with body scald burns who presents with stridor or respiratory distress [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21464/abstract/15\">",
"     15",
"    </a>",
"    ]. Smoke or steam inhalation can cause direct thermal injury to the upper respiratory tract. Microwave-heated liquids are the most common cause of thermal epiglottitis and edematous arytenoidal tissue in infants and young children. The clinical presentation of thermal epiglottitis injuries in children may be similar to that of acute infectious epiglottitis, and should be managed as an emergency airway obstruction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/61/10201?source=see_link\">",
"     \"Emergent evaluation of acute upper airway obstruction in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chronic or recurrent episodes of stridor may suggest an exogenous compression of the airway caused by a foreign body, subglottic stenosis, vascular rings, or a tumor. Asthma can also present as recurrent noisy breathing associated with cough and exercise intolerance. Intermittent episodes of stridor or wheezing in which the onset and cessation are abrupt may indicate vocal cord dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30424?source=see_link\">",
"     \"Approach to wheezing in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/41/1689?source=see_link\">",
"     \"Wheezing illnesses other than asthma in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Associated symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever is usually present with infectious etiologies. In more serious bacterial infections, the child will appear ill or toxic. However, the presence of an elevated temperature neither diagnoses nor excludes bacterial infection. Up to 25 percent of patients with a serious bacterial infection (eg, epiglottitis and abscesses) are not febrile on presentation to the physician, while a significant number of children with croup have elevated temperatures [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21464/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43529?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical features, evaluation, and diagnosis of croup\", section on 'Clinical presentation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/45/4826?source=see_link\">",
"     \"Epiglottitis (supraglottitis): Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43992?source=see_link\">",
"     \"Retropharyngeal infections in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Drooling and a muffled voice usually suggest that the obstruction is supraglottic, whereas drooling and dysphagia can occur if a foreign body in the trachea or a mass compresses the anterior esophageal wall. If there is a change in the voice tone that accompanies the stridor, a laryngeal lesion such as vocal cord injury due to inflammation (eg, croup) or paralysis should be suspected [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21464/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alteration in mental status (lethargy, anxiety) with increased work of breathing can point to an impending airway obstruction. Respiratory distress and stridor related to feeding can be caused by aspiration either secondary to swallowing dysfunction or gastroesophageal reflux. Presence of rash, hypotension, and wheezing with acute onset of stridor indicates an allergic reaction with angioedema. (\"Clinical manifestations and diagnosis of gastroesophageal reflux disease in infants and children\").",
"   </p>",
"   <p>",
"    If a patient develops airway obstructive episodes during sleep, it is most likely that the origin of the stridor arises from the pharynx, in which case, the tonsils and adenoids should be evaluated. On the other hand, if stridor is noticed to be more significant while the patient is awake, and even more pronounced during exercise, then the possibility of a laryngeal, tracheal, or bronchial obstruction should be suspected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/38/44649?source=see_link\">",
"     \"Evaluation of suspected obstructive sleep apnea in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Past medical history",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough past medical history should be elicited, and should include the prenatal and perinatal period (eg, infections, prematurity, complicated delivery, necessity of intubation and mechanical ventilation). Any significant surgical history, (patent ductus arteriosus ligation, cardiac or neck surgery) should be assessed. It is important to learn whether there have been previous admissions secondary to respiratory diseases, and whether the patient ever required prolonged intubation. Potential exposure to food or environmental allergens that might trigger laryngeal edema may be helpful in the differential diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A clinician should look for a number of important features when evaluating a child with stridor. First of all, it is critically important to quickly identify any patient with impending airway obstruction. Once identified, therapy should be initiated to prevent central airway obstruction before performing any diagnostic tests. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/61/7130?source=see_link\">",
"     \"Emergent evaluation of acute respiratory compromise in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the patient is stable and immediate therapy is not required, then a detailed physical examination and diagnostic testing can be conducted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29030?source=see_link\">",
"     \"Basic airway management in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22327?source=see_link\">",
"     \"Initial assessment and stabilization of children with respiratory or circulatory compromise\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Inspection should include evaluation both during rest and after activity. Measurement of height and weight are important in evaluating whether the child is failing to thrive, or is obese. Special notice should be given to the size of the tongue and mandible, and the presence of any craniofacial malformation. Surgical scars around the upper chest or neck might indicate vocal cord lesion, or tracheal or subglottic stenosis. Neck edema accompanied by fever suggests a retropharyngeal or peritonsillar abscess. The patient's work of breathing should be assessed, including the presence of cyanosis, nasal flaring, and retractions. An intrathoracic process, such as infection or tumor compressing the airway, may also cause peripheral lymphadenopathy. Clubbing may suggest an underlying congenital heart disease or bronchiectasis. Hemangiomas may be present in multiple parts of the body, including skin and airway. Caf&eacute; au lait spots are also associated with head and neck neurofibromas, which can involve the airway.",
"   </p>",
"   <p>",
"    The most helpful features of the physical examination are found on auscultation. The stethoscope bell should be placed over the child's mouth and neck to determine the origin of the stridor. Stridor is primarily heard during inspiration, but can be heard during expiration or throughout the respiratory cycle.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nasal, nasopharyngeal, or oropharyngeal obstruction results in a snoring, low-pitched sound that may be identified with or without a stethoscope",
"     </li>",
"     <li>",
"      Inspiratory stridor is associated with obstruction above the glottis",
"     </li>",
"     <li>",
"      Expiratory stridor is more likely to be the result of an intrathoracic obstruction",
"     </li>",
"     <li>",
"      Biphasic stridor suggests either critical or fixed obstruction (at any level), or an obstruction in the area between the glottis and subglottis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Diagnostic testing",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Radiological findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiography, when appropriately obtained, can be a useful tool in evaluating the child with stridor. Prior to obtaining any radiographs, the clinician needs to evaluate the child and assess the risk of developing complete airway obstruction. If any life-threatening situation is suspected, the patient must be accompanied to the radiology suite by appropriate medical personnel with the equipment necessary for airway management, including emergent tracheotomy or cricothyroidotomy. In the stable patient, radiological testing is an appropriate complement to history and physical examination.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neck radiographs &ndash; Plain neck films are usually non-specific, but may reveal changes associated with retropharyngeal abscess, epiglottitis, croup, or a radiopaque foreign body",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Retropharyngeal abscesses can be diagnosed on plain radiography; findings include a retropharyngeal space greater than 7 mm anterior to the inferior border of the second cervical vertebral body, or a retrotracheal space greater than 14 mm in children anterior to the inferior border of the sixth cervical vertebral body (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63233 \" href=\"UTD.htm?23/20/23887\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21464/abstract/19\">",
"     19",
"    </a>",
"    ]. Other findings include soft tissue air-fluid levels, and cervical retro flexion. Overexposed anteroposterior and lateral projection views obtained may help to identify soft tissue abnormalities.",
"   </p>",
"   <p>",
"    Anteroposterior and lateral neck radiographs are sometimes used in evaluating children with suspected laryngotracheobronchitis caused by croup [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21464/abstract/20\">",
"     20",
"    </a>",
"    ]. The \"steeple\" sign occurs when the subglottic arch becomes edematous and shows an inverted \"V\" in the anteroposterior view (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52418 \" href=\"UTD.htm?2/56/2959\">",
"     image 2",
"    </a>",
"    ). In the lateral view, the hypopharynx is distended and there is subglottic haziness. The epiglottis is normal (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64727 \" href=\"UTD.htm?41/59/42943\">",
"     image 3",
"    </a>",
"    ). Unfortunately, the diagnostic value of this finding is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21464/abstract/21\">",
"     21",
"    </a>",
"    ]. If lateral neck radiographs show an edematous epiglottis with the thumb sign (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67878 \" href=\"UTD.htm?22/26/22958\">",
"     image 4",
"    </a>",
"    ), enlarged aryepiglottic folds, and a ballooned hypopharyngeal airway, epiglottitis should be considered. However, these findings are subjective, and as many as 70 percent of all patients with epiglottitis have radiographic findings interpreted as normal [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21464/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Generally, stable children with suspected epiglottitis might have a lateral neck radiograph in a controlled environment. If the patient is unstable, an emergency evaluation of the airway in the operating room is indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/45/4826?source=see_link\">",
"     \"Epiglottitis (supraglottitis): Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chest radiographs &ndash; In cases where an intrathoracic problem is suspected, a plain chest radiograph should be obtained. Plain radiographs can demonstrate mediastinal lymphadenopathy or masses. Findings suggestive of vascular rings, including a right aortic arch, may also be present on plain films (",
"      <a class=\"graphic graphic_table graphicRef51295 \" href=\"UTD.htm?11/25/11675\">",
"       table 2",
"      </a>",
"      ). Findings suggestive of foreign body aspiration include mediastinal shift, unilateral hyperinflation, atelectasis, or the actual foreign body, if it is radiopaque. However, a normal chest radiograph cannot completely rule out an airway foreign body because most of the objects aspirated by children are radiolucent [",
"      <a class=\"abstract\" href=\"UTD.htm?20/61/21464/abstract/24,25\">",
"       24,25",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2585?source=see_link\">",
"       \"Airway foreign bodies in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other studies &ndash; Airway fluoroscopy may be helpful in detecting tracheomalacia, since it shows the airway dynamics during breathing.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"       Barium",
"      </a>",
"      swallow is a useful test to identify swallowing dysfunction, vascular rings, mediastinal masses, or esophageal abnormalities, as well as gastroesophageal reflux [",
"      <a class=\"abstract\" href=\"UTD.htm?20/61/21464/abstract/26\">",
"       26",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/41/41625?source=see_link\">",
"       \"Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Computed tomography (CT) scan of the chest and neck can be helpful in the diagnosis of retropharyngeal cellulitis with compression of the pyriform sinuses and an anterior deviation of the trachea. It is also used to look for enlarged lymph nodes, tumors, aberrant arteries, and vascular rings. In addition, it may show narrowing of the airway suggestive of tracheal stenosis. The greatest disadvantage of CT is its limited ability to image the trachea across the long axis, in which case magnetic resonance imaging (MRI) offers better resolution. When performed without contrast injection, MRI can also provide a good evaluation of the mediastinum, and estimates the length and degree of a tracheal stenosis or obstruction, if present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25256?source=see_link\">",
"     \"Radiology of the trachea\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Traditionally, angiography was the gold standard for diagnosing vascular rings and related abnormalities, including a right aortic arch. However, since the development of MRI technology, which provides excellent visualization of vascular structures and the large airways, most centers use MRI as the next diagnostic test after plain radiography, decreasing the need for catheterization and angiography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Spirometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spirometry is difficult to perform in children, especially in young infants, who are more likely to have stridor. In general, it can be done in children over six years of age. The configuration of the flow-volume loop may help distinguish the site of the obstruction, its variability, and its response to bronchodilators. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25878?source=see_link\">",
"     \"Flow-volume loops\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Three patterns of obstruction are identified by the flow-volume loop:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Variable extrathoracic obstruction &ndash; The presence of a non-rigid extrathoracic obstruction (ie, vocal cord paralysis) leads to an increase in obstruction during inspiration (",
"      <a class=\"graphic graphic_figure graphicRef65386 \" href=\"UTD.htm?17/3/17470\">",
"       figure 1",
"      </a>",
"      ), with flow-volume loop showing flattening of the inspiratory component (",
"      <a class=\"graphic graphic_figure graphicRef76811 \" href=\"UTD.htm?34/31/35325\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Variable intrathoracic obstruction &ndash; The presence of intrathoracic obstruction is more pronounced during expiration, resulting in compression of the lower trachea or main bronchus (",
"      <a class=\"graphic graphic_figure graphicRef55931 \" href=\"UTD.htm?14/54/15214\">",
"       figure 2",
"      </a>",
"      ). Flow volume loops will show a flat expiratory component (",
"      <a class=\"graphic graphic_figure graphicRef76811 \" href=\"UTD.htm?34/31/35325\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Fixed upper airway obstruction &ndash; As there is limited flow when there is a fixed obstruction (foreign body, tracheal stenosis, or endobronchial tumors), the curve will show flattening of both inspiratory and expiratory components (",
"      <a class=\"graphic graphic_figure graphicRef76811 \" href=\"UTD.htm?34/31/35325\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Airway examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visualization of the airways allows definitive diagnosis of the cause of stridor in children. It is important to keep in mind that more than one airway abnormality may be present in the same child and a thorough evaluation of the upper and lower airways may be warranted.",
"   </p>",
"   <p>",
"    Airway visualization should be promptly performed if the underlying cause of stridor in an acutely ill child is thought to be epiglottitis (",
"    <a class=\"graphic graphic_picture graphicRef74563 \" href=\"UTD.htm?28/19/28978\">",
"     picture 1",
"    </a>",
"    ) or bacterial tracheitis (",
"    <a class=\"graphic graphic_picture graphicRef55364 \" href=\"UTD.htm?16/55/17264\">",
"     picture 2",
"    </a>",
"    ). This procedure should be performed in a facility equipped with appropriately sized resuscitation equipment, and by clinicians with experience in managing pediatric airways.",
"   </p>",
"   <p>",
"    When the patient has a stable airway, a nasopharyngoscopy can be performed in an unsedated and awake child at the bedside. Nasopharyngoscopy is useful in the diagnosis of laryngomalacia and anatomic defects between the nose and pharynx, as well as in the assessment of vocal cord movement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16567?source=see_link\">",
"     \"Paradoxical vocal cord motion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the patient does not have a stable airway, flexible or rigid laryngoscopy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bronchoscopy is indicated. These procedures should be performed in the operating room, with anesthesia, sedation, and continuous monitoring. Direct laryngoscopy is safe in cases of suspected epiglottitis, with little risk of complications such as laryngospasm [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21464/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/61/10201?source=see_link\">",
"     \"Emergent evaluation of acute upper airway obstruction in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Flexible or rigid laryngoscopy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bronchoscopy is also indicated If the patient is stable but needs a thorough evaluation of the airways for diagnostic purposes. Rigid laryngoscopy and bronchoscopy are the gold standard for evaluation and diagnosis of subglottic, tracheal, and central airway lesions. The rigid bronchoscope allows the clinician to take biopsy samples, remove foreign bodies, and dilate stenosed airways if necessary. If a foreign body is not suspected, a flexible bronchoscope is usually used, and the examination is performed during spontaneous breathing to help identify abnormalities in airway dynamics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37351?source=see_link\">",
"     \"Diagnosis and management of central airway obstruction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2585?source=see_link&amp;anchor=H9#H9\">",
"     \"Airway foreign bodies in children\", section on 'Diagnosis and management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stridor is a monophonic, high-pitched sound, usually caused by upper airway narrowing and partial obstruction. If the airway narrowing is in the nasal, nasopharyngeal, oropharyngeal areas the noise generated is typically of low pitch and is referred to as snoring or stertor. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Anatomy and etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Stridor originating from the extrathoracic area is more pronounced during inspiration, and tends to abate during exhalation. Stridor caused by obstruction at the glottis (vocal cords) may occur during inspiration only, or during both inspiration and expiration. Intrathoracic airway compression usually gives rise to wheezing, although compression of the proximal trachea can result in expiratory stridor. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Anatomy and etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Critical and fixed airway obstruction typically results in biphasic inspiratory and expiratory stridor. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of stridor includes common benign conditions as well as disorders that can rapidly progress, leading to complete airway obstruction and death (",
"      <a class=\"graphic graphic_table graphicRef62718 graphicRef71405 \" href=\"UTD.htm?5/6/5230\">",
"       table 1A-B",
"      </a>",
"      ). Clinical history, physical examination, radiographs, and spirometry may provide clues to the cause of stridor. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The child who has a complete airway obstruction must be identified immediately and life-saving maneuvers initiated. Although the etiology of the obstruction must be considered, the response to therapeutic interventions directs initial management (",
"      <a class=\"graphic graphic_algorithm graphicRef55990 \" href=\"UTD.htm?22/48/23296\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Airway examination'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/61/10201?source=see_link&amp;anchor=H40#H40\">",
"       \"Emergent evaluation of acute upper airway obstruction in children\", section on 'Imminent decompensation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21464/abstract/1\">",
"      Rothrock, SG, Perkin, R. Stridor: A review, update and current management recommendations. Pediatric Emerg Med Rep 1996; 4:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21464/abstract/2\">",
"      Forgacs P. The functional basis of pulmonary sounds. Chest 1978; 73:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21464/abstract/3\">",
"      Hollingsworth HM. Wheezing and stridor. Clin Chest Med 1987; 8:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21464/abstract/4\">",
"      Gilbert EG, Russell KE, Deskin RW. Stridor in the infant and child. Assessment, treatment. AORN J 1993; 58:23, 26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21464/abstract/5\">",
"      Murphy, RLH, Hoford, SK. Lung sounds. ATS News 1980; 8:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21464/abstract/6\">",
"      Boudewyns A, Claes J, Van de Heyning P. Clinical practice: an approach to stridor in infants and children. Eur J Pediatr 2010; 169:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21464/abstract/7\">",
"      Kussman BD, Geva T, McGowan FX. Cardiovascular causes of airway compression. Paediatr Anaesth 2004; 14:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21464/abstract/8\">",
"      De Ugarte DA, Shapiro NL, Williams HL. Tuberculous mediastinal mass presenting with stridor in a 3-month-old child. J Pediatr Surg 2003; 38:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21464/abstract/9\">",
"      Ahmed I, Kureel SN, Chandra N. Stridor with recurrent chest infection. Asian Cardiovasc Thorac Ann 2011; 19:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21464/abstract/10\">",
"      Busino RS, Quraishi HA, Cohen IT. Stridor secondary to a bronchogenic cyst in a neonate. Ear Nose Throat J 2011; 90:E8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21464/abstract/11\">",
"      Leboulanger N, Garab&eacute;dian EN. Laryngo-tracheo-oesophageal clefts. Orphanet J Rare Dis 2011; 6:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21464/abstract/12\">",
"      Platzker, A, Lew, C. Childhood pulmonary aspiration. Semin Respir Med 1990; 2:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21464/abstract/13\">",
"      Gorelick MH, Baker MD. Epiglottitis in children, 1979 through 1992. Effects of Haemophilus influenzae type b immunization. Arch Pediatr Adolesc Med 1994; 148:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21464/abstract/14\">",
"      Hopkins A, Lahiri T, Salerno R, Heath B. Changing epidemiology of life-threatening upper airway infections: the reemergence of bacterial tracheitis. Pediatrics 2006; 118:1418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21464/abstract/15\">",
"      D'Agostino J. Pediatric airway nightmares. Emerg Med Clin North Am 2010; 28:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21464/abstract/16\">",
"      Losek JD, Dewitz-Zink BA, Melzer-Lange M, Havens PL. Epiglottitis: comparison of signs and symptoms in children less than 2 years old and older. Ann Emerg Med 1990; 19:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21464/abstract/17\">",
"      Couriel JM. Management of croup. Arch Dis Child 1988; 63:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21464/abstract/18\">",
"      Leung AK, Cho H. Diagnosis of stridor in children. Am Fam Physician 1999; 60:2289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21464/abstract/19\">",
"      Barratt GE, Koopmann CF Jr, Coulthard SW. Retropharyngeal abscess--a ten-year experience. Laryngoscope 1984; 94:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21464/abstract/20\">",
"      Mills JL, Spackman TJ, Borns P, et al. The usefulness of lateral neck roentgenograms in laryngotracheobronchitis. Am J Dis Child 1979; 133:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21464/abstract/21\">",
"      Stankiewicz JA, Bowes AK. Croup and epiglottitis: a radiologic study. Laryngoscope 1985; 95:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21464/abstract/22\">",
"      Diaz JH, Lockhart CH. Early diagnosis and airway management of acute epiglottitis in children. South Med J 1982; 75:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21464/abstract/23\">",
"      Rothrock SG, Pignatiello GA, Howard RM. Radiologic diagnosis of epiglottitis: objective criteria for all ages. Ann Emerg Med 1990; 19:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21464/abstract/24\">",
"      Steen KH, Zimmermann T. Tracheobronchial aspiration of foreign bodies in children: a study of 94 cases. Laryngoscope 1990; 100:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21464/abstract/25\">",
"      Losek JD. Diagnostic difficulties of foreign body aspiration in children. Am J Emerg Med 1990; 8:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21464/abstract/26\">",
"      Gilger MA. Pediatric otolaryngologic manifestations of gastroesophageal reflux disease. Curr Gastroenterol Rep 2003; 5:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21464/abstract/27\">",
"      MayoSmith MF, Hirsch PJ, Wodzinski SF, Schiffman FJ. Acute epiglottitis in adults. An eight-year experience in the state of Rhode Island. N Engl J Med 1986; 314:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21464/abstract/28\">",
"      Mauro RD, Poole SR, Lockhart CH. Differentiation of epiglottitis from laryngotracheitis in the child with stridor. Am J Dis Child 1988; 142:679.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6380 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-60.18.131.125-10F4DE3033-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_61_21464=[""].join("\n");
var outline_f20_61_21464=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY AND ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Extrathoracic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Supraglottic area",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Glottic and subglottic area",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Intrathoracic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Age",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Acuity of onset and severity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Associated symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Past medical history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Radiological findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Spirometry",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Airway examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6380\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6380|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?22/48/23296\" title=\"algorithm 1\">",
"      Complete airway obstruction in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6380|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?23/20/23887\" title=\"diagnostic image 1\">",
"      Retropharyngeal abscess plain radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/56/2959\" title=\"diagnostic image 2\">",
"      Steeple sign",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/59/42943\" title=\"diagnostic image 3\">",
"      Croup lateral neck",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?22/26/22958\" title=\"diagnostic image 4\">",
"      Epiglottitis x-ray",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6380|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/3/17470\" title=\"figure 1\">",
"      Effect of dynamic extrathoracic airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/54/15214\" title=\"figure 2\">",
"      Effects of dynamic intrathoracic airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/31/35325\" title=\"figure 3\">",
"      Flow volume loops in airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6380|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/19/28978\" title=\"picture 1\">",
"      Acute epiglottitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/55/17264\" title=\"picture 2\">",
"      Bacterial tracheitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6380|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/12/2253\" title=\"table 1A\">",
"      Congenital anomalies associated with stridor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/49/38684\" title=\"table 1B\">",
"      Causes of stridor other than congenital anomalies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/25/11675\" title=\"table 2\">",
"      Chest radiograph findings in vascular rings",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2585?source=related_link\">",
"      Airway foreign bodies in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/9/17561?source=related_link\">",
"      Approach to chronic cough in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41417?source=related_link\">",
"      Approach to diagnosis of acute infectious pharyngitis in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30424?source=related_link\">",
"      Approach to wheezing in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32536?source=related_link\">",
"      Bacterial tracheitis in children: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29030?source=related_link\">",
"      Basic airway management in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43529?source=related_link\">",
"      Clinical features, evaluation, and diagnosis of croup",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/41/41625?source=related_link\">",
"      Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29114?source=related_link\">",
"      Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/42/37543?source=related_link\">",
"      Congenital anomalies of the larynx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37351?source=related_link\">",
"      Diagnosis and management of central airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/61/7130?source=related_link\">",
"      Emergent evaluation of acute respiratory compromise in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/61/10201?source=related_link\">",
"      Emergent evaluation of acute upper airway obstruction in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/38/29287?source=related_link\">",
"      Epidemiology, pathophysiology and clinical manifestations of diphtheria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/45/4826?source=related_link\">",
"      Epiglottitis (supraglottitis): Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/29/44505?source=related_link\">",
"      Etiology and management of hoarseness in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/38/44649?source=related_link\">",
"      Evaluation of suspected obstructive sleep apnea in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25878?source=related_link\">",
"      Flow-volume loops",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22327?source=related_link\">",
"      Initial assessment and stabilization of children with respiratory or circulatory compromise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16567?source=related_link\">",
"      Paradoxical vocal cord motion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25256?source=related_link\">",
"      Radiology of the trachea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43992?source=related_link\">",
"      Retropharyngeal infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/5/27735?source=related_link\">",
"      Vascular rings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/41/1689?source=related_link\">",
"      Wheezing illnesses other than asthma in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_61_21465="Temporary cardiac pacing";
var content_f20_61_21465=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Temporary cardiac pacing",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/61/21465/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/61/21465/contributors\">",
"     Brian Olshansky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/61/21465/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/61/21465/contributors\">",
"     Leonard I Ganz, MD, FHRS, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/61/21465/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/61/21465/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/61/21465/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Temporary cardiac pacing involves electrical cardiac stimulation to treat a tachyarrhythmia or bradyarrhythmia until it resolves or until long-term therapy can be initiated. The purpose of temporary pacing is the reestablishment of circulatory integrity and normal hemodynamics that are acutely compromised by a slow or fast heart rate by maintaining an appropriate heart rate; in some situations, temporary pacing can be lifesaving.",
"   </p>",
"   <p>",
"    This topic will review insertion techniques and proper approach to follow-up of, and indications for, temporary pacing. Issues related to permanent pacing are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1849?source=see_link\">",
"     \"Modes of cardiac pacing: Nomenclature and selection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27463?source=see_link\">",
"     \"Indications for permanent cardiac pacing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TECHNICAL SKILLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to implantation, knowledge about normal anatomy and endocardial structures and the ability to distinguish between normal electrograms and artifact are important to guide proper lead positioning. An",
"    <span class=\"nowrap\">",
"     ACP/ACC/AHA",
"    </span>",
"    task force, and others, have made recommendations about numbers of devices that a clinician needs to place to be considered competent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21465/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Invasive, hemodynamic skills must be demonstrated by performing a minimum of 25 procedures. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25221?source=see_link\">",
"       \"Insertion of pulmonary artery catheters\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A minimum of 10 ventricular temporary pacemaker implants is suggested.",
"     </li>",
"     <li>",
"      Technical skills, adhering to strict surgical sterile technique, including the ability to perform venous access from two or multiple sites using a percutaneous or cut down approach are necessary.",
"     </li>",
"     <li>",
"      The ability to perform and operate all instrumentation must be demonstrated. This includes use of pacing catheters, ability to correct technical problems with pacing instrumentation and pacing catheters, and ability to obtain sufficient and high quality data.",
"     </li>",
"     <li>",
"      To maintain competence, hospitals should require continuous experience for clinicians and at least one to two pacemaker implants per year are recommended.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MODES OF TEMPORARY CARDIAC PACING",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of pacing modes are available for temporary use; pacing can be atrial (AOO, AAI), ventricular (VVI, VOO), or dual chamber (DDI, DDD, VDD [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21465/abstract/6\">",
"     6",
"    </a>",
"    ], or DVI) (",
"    <a class=\"graphic graphic_table graphicRef68327 graphicRef79459 \" href=\"UTD.htm?2/32/2573\">",
"     table 1A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1849?source=see_link\">",
"     \"Modes of cardiac pacing: Nomenclature and selection\"",
"    </a>",
"    .) Pacing can be asynchronous or demand although, with dual chamber pacing atrial, sensing can trigger ventricular pacing.",
"   </p>",
"   <p>",
"    The most frequent use of temporary pacing is for therapy of symptomatic bradycardia due to either sinus node dysfunction or atrioventricular (AV) nodal block. Once pacing is initiated for bradycardia, the patient can become rapidly dependent on the pacemaker [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21465/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. In this setting, dislodgement of the lead or failure of the pacer to capture can result in asystole, which may not have otherwise occurred.",
"   </p>",
"   <p>",
"    Antitachycardia pacing involves intermittent overdrive pacing, usually at a rate more rapid than the tachycardia, to prevent, or more commonly to terminate, a reentrant circuit that may be located in the atria, the ventricles, or the AV node [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21465/abstract/9-17\">",
"     9-17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24793?source=see_link\">",
"     \"Atrioventricular nodal reentrant tachycardia (junctional reciprocating tachycardia)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/49/18201?source=see_link\">",
"     \"Restoration of sinus rhythm in atrial flutter\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antitachycardia pacing requires sophisticated knowledge about the pacing and arrhythmia, since it may result in acceleration of the tachycardia rate or transform the tachycardia into another arrhythmia (eg, atrial flutter to atrial fibrillation or ventricular tachycardia to ventricular fibrillation). The more rapid the overdrive pacing rate, the more likely that a faster, more poorly tolerated arrhythmia may be induced.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     APPROACHES TO TEMPORARY PACING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Temporary pacing can be performed with:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Internal or endocardial leads [",
"      <a class=\"abstract\" href=\"UTD.htm?20/61/21465/abstract/18-28\">",
"       18-28",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Atrial or ventricular epicardial leads placed at the time of surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?20/61/21465/abstract/29-31\">",
"       29-31",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      External or transthoracic patches [",
"      <a class=\"abstract\" href=\"UTD.htm?20/61/21465/abstract/32-39\">",
"       32-39",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Transcutaneous insertion via a needle placed directly through the chest wall",
"     </li>",
"     <li>",
"      An esophageal electrode, which is primarily used for atrial pacing and recording [",
"      <a class=\"abstract\" href=\"UTD.htm?20/61/21465/abstract/14,40,41\">",
"       14,40,41",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Types of electrode catheters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various types of electrode catheters are available. Endocardial pacing catheters are stiff but can be balloon-tipped for easier insertion [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21465/abstract/25\">",
"     25",
"    </a>",
"    ]. They come with various curves, including a preformed atrial \"J\" wire, and in 2, 5, 6, and 7 French sizes; they are generally bipolar or quadripolar. Stiff endocardial leads can maintain stability over a period of time, but careful positioning is recommended.",
"   </p>",
"   <p>",
"    Endocardial screw-in temporary leads can be used to help maintain stability. These leads, purposefully flimsy, are thin and deployed through a sheath that is then removed. Two such leads can be placed from one vein, if needed, and maintained with no indwelling intravenous access. These leads can maintain excellent pacing and sensing thresholds for many days. Epicardial wires have unipolar and bipolar design. Electrode catheters can be used to pace atria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ventricles.",
"   </p>",
"   <p>",
"    In general atrial leads are not inserted when bradycardia alone is the indication for pacing. However, an atrial lead is inserted for pace termination of atrial tachyarrhythmias, particularly atrial flutter, and to provide AV synchrony if a dual chamber pacing system is required [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21465/abstract/42-51\">",
"     42-51",
"    </a>",
"    ]. Atrial pacing may be crucial in situation where a junctional rhythm is present with hemodynamic compromise. Atrial pacing may provide hemodynamic advantage in patients with diastolic dysfunction, such as those early after cardiac (especially valvular) surgery. The benefits of atrial pacing for conditions of sinus bradycardia or junctional rhythm are most prominent after cardiac surgery for patient with ischemia, ventricular hypertrophy, or heart failure",
"   </p>",
"   <p>",
"    Transthoracic pacing patches are high impedance to cause better current density and less pain. Esophageal leads are actually permanent pacemaker leads that are placed within the esophagus at the level of the left atrium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Insertion techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuous electrocardiographic monitoring is recommended during the insertion of an endocardial pacing lead [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21465/abstract/1,2,52-56\">",
"     1,2,52-56",
"    </a>",
"    ]. Fluoroscopy is not necessary but is desirable. If fluoroscopy is not available, a balloon-tipped catheter is easiest to place. There are several settings in which a particular approach is less or more desirable.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A balloon-tipped catheter cannot be used, because of inadequate blood flow, if pacing is required during resuscitation for a patient who has had a cardiac arrest.",
"     </li>",
"     <li>",
"      A pacing Swan-Ganz catheter is less stable and should not be relied upon for a patient who is pacemaker dependent.",
"     </li>",
"     <li>",
"      If the patient has had recent open heart surgery, epicardial electrodes are usually present and can be used instead of inserting a temporary transvenous endocardial lead.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are several important issues in regard to implantation techniques:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Access site",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best access site for temporary pacing leads is via the left subclavian vein or the right internal jugular vein. Brachial and femoral approaches are not recommended because of the risk of cardiac puncture and instability using a brachial approach and the risk of deep vein thrombosis and infection using the femoral approach. Direct cardiac puncture is rarely needed.",
"   </p>",
"   <p>",
"    Although the right internal jugular approach is usually preferred, the best approach to minimize complications is the one with which the clinician has the most experience. When a patient is pacemaker-dependent, it is crucial that the lead be placed in a stable position and fluoroscopy should be used whenever possible.",
"   </p>",
"   <p>",
"    The subclavian approach permits more freedom of patient motion and might be useful in a patient who requires a long-term temporary pacemaker. However, once the pacemaker is in place, a permanent pacemaker should not be implanted on that side due to the risk of infection.",
"   </p>",
"   <p>",
"    After obtaining venous access, a modified Seldinger technique is usually used; a peel away sheath is recommended if the lead is to be in place for more than five days. Another approach is to use a sheath with a sterile connector covering so that the lead can be repositioned at a later time.",
"   </p>",
"   <p>",
"    A temporary pacemaker placed in the subclavian or right internal jugular that has been inserted in a sheath (or without an indwelling introducer sheath) that does not allow for intravenous infusion can be maintained for long as 7 to 10 days without major concern. However there is a need for careful care and proper bandaging of the site to prevent infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Lead placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the lead is placed in the right ventricular apex, there should be slight excess lead (pressure at the tip, with a bend at the tricuspid ring) to insure that the lead does not become dislodged. The lead should be tied down in at least two different sites, one where the lead exits from the vein and the other to a loop formed with the lead. The loop should be large enough to prevent tension on the lead, preventing it from becoming dislodged and the pacemaker losing capture.",
"   </p>",
"   <p>",
"    For the patient who has symptomatic bradycardia and requires temporary pacing, transthoracic or external pacing, if available, should be used before a temporary wire is placed. External pacing functions only in a VVI mode and is only used for emergent pacing. It should not be relied upon if temporary pacing for a longer period of time is required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Pacemaker system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several types of pulse generators are available which permit single and dual chamber pacing. The single chamber units function in a VVI or AAI mode if demand pacing is used or in a VOO or AOO mode when fixed rate pacing is preferred; the dual chamber modes are DOO (fixed rate), DVI or DDD (",
"    <a class=\"graphic graphic_table graphicRef68327 graphicRef79459 \" href=\"UTD.htm?2/32/2573\">",
"     table 1A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1849?source=see_link\">",
"     \"Modes of cardiac pacing: Nomenclature and selection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The connector cable linking the catheter lead to the pacemaker generator is a simple aspect of the system, but it is important for these connectors to be screwed tightly and securely fastened with a clamp. An improper connection or inadvertent disconnection can result in pacing malfunction or even asystole and possibly death in a patient who is pacemaker-dependent. Even if a patient is not initially pacemaker-dependent but is then paced, abrupt disconnection of the pacing or turning off of the pacemaker could lead to asystole due to newly acquired pacemaker-dependence [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21465/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To insure proper pacemaker sensing and capture, the pacemaker output should be set at least two to three times the pacing threshold (ie, the minimum current in milliamps and, therefore, energy necessary for pacemaker capture) and two to three times the sensing threshold. The threshold, especially in the ventricle, should be less than or equal to 1 milliamp, especially for the patient who is pacemaker-dependent",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Transesophageal pacing",
"    </span>",
"    &nbsp;&mdash;&nbsp;A transesophageal pacemaker lead can be used for atrial pacing",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    recording. It can be inserted through the mouth or the nose, depending upon the type of catheter used. However, the catheter is uncomfortable to place, pacing is unreliable, and pain is common because it requires high current and pulse width for adequate and continual capture. For these reasons, transesophageal pacing is not routinely used, although it may have a role in pediatrics for diagnostic purposes. It has also been of some use for pace termination of atrial tachycardia or atrial flutter and for establishing the presence of P waves if they are not obvious on the electrocardiogram.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Epicardial pacing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epicardial pacing leads are often placed after cardiac surgery and can be used for temporary pacing if bradycardia occurs, or for overdrive pacing of a postoperative atrial tachyarrhythmia, especially atrial flutter. There are unipolar or bipolar types and the leads may be located in the atrium, ventricle, or both chambers.",
"   </p>",
"   <p>",
"    Lead longevity is a problem since these leads last only for several days to as long as one week. One concern is that, when present for more than one week, the pacing threshold will rise and there may not be adequate and reliable capture. The leads should not be used and should be removed if this occurs. There are several other precautions that must be taken when epicardial leads are in place, especially capping them because of a risk for the initiation of ventricular fibrillation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     External pacing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large chest wall electrodes with a high impedance interface are required for external pacing. However, it causes significant discomfort and sedation or a state of unconsciousness are required to use this approach effectively for more than back-up or emergency pacing. Reliability limits its use and it is often difficult to determine if there is adequate ventricular capture.",
"   </p>",
"   <p>",
"    External pacing has been used in the following situations (",
"    <a class=\"graphic graphic_table graphicRef76744 \" href=\"UTD.htm?4/58/5036\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During an asystolic cardiac arrest, although there is little evidence that external pacing is successful in this setting. Randomized studies which have compared external pacing by paramedics with other approaches to treat asystole have shown little difference in mortality, and survival is poor regardless of the approach used [",
"      <a class=\"abstract\" href=\"UTD.htm?20/61/21465/abstract/32,33,38\">",
"       32,33,38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      As prophylaxis during catheter manipulation in the right ventricle, particularly when there is a left bundle branch block, and as prophylaxis in patients with a reversible cause for bradycardia.",
"     </li>",
"     <li>",
"      As standby therapy for patients at high risk for developing a symptomatic bradycardia such as those with an asymptomatic bradycardia who require pharmacologic therapy that may worsen the bradycardia or for patients with an acute myocardial infarction who have a conduction abnormality that may result in a serious bradycardia.",
"     </li>",
"     <li>",
"      As a method to overdrive and pace terminate a sustained tachyarrhythmia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Management of temporary pacemaker electrodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuous monitoring is mandatory during the entire time the patient has a temporary pacemaker, and a separate intravenous line or a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    lock is recommended should there be a need for drug therapy. Patients with temporary pacemakers require a daily check of pacing thresholds to make certain that there is proper capture and sensing, and at least one 12-lead electrocardiogram recorded during pacing to determine the electrocardiographic appearance of the QRS complex to insure the proper location of the leads. The endocardial ventricular lead should be at the apex and, when the pacemaker is in the proper position, the QRS should have a left bundle branch block morphology and a superior axis (ie, an upright QRS complex in lead I and aVL) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21465/abstract/52-56\">",
"     52-56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A chest x-ray should be obtained to determine the position of the endocardial leads. This test should be repeated if there is failure to capture or sense or a ventricular tachyarrhythmia occurs which suggests electrode dislodgement.",
"   </p>",
"   <p>",
"    A physical examination should be performed regularly to evaluate for a pericardial friction rub, which is indicative of a perforation; for the presence of asymmetrical or absent breaths sounds, indicating the presence of a pneumothorax; for hypotension and jugular venous distension that would suggest tamponade or a pacing problem; or fever suggestive of an infection. In addition, the need for continuous pacing should be established.",
"   </p>",
"   <p>",
"    The dressing at the site of pacemaker insertion should be changed daily and antibiotic ointment applied to prevent infection. The stability of the wire and the loop should be checked to prevent inadvertent dislodgement of the lead. All connections and pacemaker programmed settings should be checked routinely.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications are not uncommon in patients treated with temporary pacing [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21465/abstract/7,57-64\">",
"     7,57-64",
"    </a>",
"    ]. Without recognition of the potential complications, adverse effects might outweigh the beneficial effects of the pacemaker.",
"   </p>",
"   <p>",
"    Serious complications of internal pacing are rare, but are important to recognize, and include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lead dislodgement and disconnection",
"     </li>",
"     <li>",
"      Bleeding",
"     </li>",
"     <li>",
"      Pericardial tamponade",
"     </li>",
"     <li>",
"      Thrombophlebitis",
"     </li>",
"     <li>",
"      Pulmonary embolism",
"     </li>",
"     <li>",
"      Catheter knotting",
"     </li>",
"     <li>",
"      Air embolism",
"     </li>",
"     <li>",
"      Various arrhythmias including ventricular tachycardia and ventricular fibrillation",
"     </li>",
"     <li>",
"      Electrical hazards, such an inadvertent induction of ventricular fibrillation",
"     </li>",
"     <li>",
"      Pneumothorax",
"     </li>",
"     <li>",
"      Subdiaphragmatic stimulation",
"     </li>",
"     <li>",
"      Infection",
"     </li>",
"     <li>",
"      Perforation",
"     </li>",
"     <li>",
"      Asystole",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Electromagnetic interference",
"    </span>",
"    &nbsp;&mdash;&nbsp;External temporary pacemakers are used mainly in intensive care units and therefore the risk of electromagnetic interference is limited. However, one experimental study found that there was a potential risk of interference of external pacemakers from walkie-talkies and cellular digital phones, which persisted at a range of up to 200 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21465/abstract/65\">",
"     65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/56/11142?source=see_link\">",
"     \"Cardiac device interactions with electromagnetic fields\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications for temporary pacing are less certain than for permanent pacing. However, any indication for permanent pacing is an appropriate indication for temporary pacing (",
"    <a class=\"graphic graphic_table graphicRef63850 \" href=\"UTD.htm?11/37/11868\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21465/abstract/8,66\">",
"     8,66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27463?source=see_link\">",
"     \"Indications for permanent cardiac pacing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Temporary pacing may also be used to determine if permanent pacing is beneficial (such as patients with symptoms suspected to be due to marked first-degree AV block, for example).",
"   </p>",
"   <p>",
"    In general, temporary pacing is indicated when a bradyarrhythmia causes severe hemodynamic impairment and when permanent pacing is not immediately indicated, not available, or the risk of inserting a permanent pacemaker exceeds potential benefit. The main reason for temporary pacing is the prevention of hemodynamic collapse or severe symptoms due to a bradycardia resulting from sinus node dysfunction, second or third degree atrioventricular block, or a hypersensitive carotid sinus.",
"   </p>",
"   <p>",
"    A difficult issue is when, and if, a temporary pacemaker is needed for such patients. As an example, a patient admitted to the hospital because of presyncope who has a single, five-second pause documented on continuous monitoring might not need a temporary pacemaker wire, particularly since its insertion might actually cause complications that would offset any potential benefit. Similarly, a patient with complete heart block who has a stable escape rhythm can usually wait for a permanent pacemaker; a temporary pacemaker in such a patient might result in pacemaker-dependence with the risk of asystole if the lead dislodges. In such patients, it is best to place a temporary pacing wire only if there is the imminent risk of asystole before a permanent pacemaker can be placed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Temporary pacing for a reversible condition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Temporary pacing is indicated for bradycardia that results from an acute and reversible cause that will likely not require permanent pacing. This includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Injury to the sinus or AV node or His-Purkinje system after heart surgery. Damage to the sinus or AV node from coronary bypass graft surgery usually improves over time. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35226?source=see_link\">",
"       \"Early noncardiac complications of coronary artery bypass graft surgery\"",
"      </a>",
"      .) In contrast, damage to the AV node or His-Purkinje system after valve surgery may not resolve, and a permanent pacemaker is required.",
"     </li>",
"     <li>",
"      Lyme disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40759?source=see_link\">",
"       \"Lyme carditis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Heart transplantation may be associated with sinus node injury and dysfunction that usually recovers over time; however, temporary pacing is often required. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/1/23576?source=see_link\">",
"       \"Arrhythmias following cardiac transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cardiac trauma, as occurs after a motor vehicle accident with associated chest trauma, may require temporary bradycardia pacing for transient asystole resulting from AV bloc that typically improves over time.",
"     </li>",
"     <li>",
"      Toxic, metabolic, electrolyte, and drug-induced causes for bradycardia including hyperkalemia,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      toxicity, beta-blocker sensitivity or overdose, and antiarrhythmic drug therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28072?source=see_link\">",
"       \"Basic approach to arrhythmias due to digoxin toxicity\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33882?source=see_link\">",
"       \"Causes and evaluation of hyperkalemia in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3704?source=see_link\">",
"       \"Major side effects of beta blockers\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Subacute bacterial endocarditis with an aortic valve abscess damaging the His-Purkinje system and causing AV block.",
"     </li>",
"     <li>",
"      Catheter trauma to the right bundle branch when a left bundle branch block is present has the potential for causing complete heart block. This problem may occur in a patient requiring hemodynamic monitoring with a Swan-Ganz catheter placed into the right ventricle. When such a patient has a left bundle branch block or a intraventricular conduction delay, the risk of developing complete heart block is less than 5 percent and prophylactic temporary endocardial pacer is not required; however, it is advisable to have external temporary pacing available [",
"      <a class=\"abstract\" href=\"UTD.htm?20/61/21465/abstract/67,68\">",
"       67,68",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27128?source=see_link\">",
"       \"Pulmonary artery catheterization: Indications and complications\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Catheter ablation of the AV node to slow the heart rate in atrial fibrillation usually results in complete heart block and requires permanent pacing. Temporary pacing is necessary until a permanent pacemaker can be placed. Temporary pacing may also be needed for patients who undergo AV nodal modification to slow conduction in the AV node during rapid rates in atrial fibrillation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24408?source=see_link\">",
"       \"Control of ventricular rate in atrial fibrillation: Nonpharmacologic therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Temporary pacing (single chamber pacing in the atrium or ventricle or dual chamber AV sequential pacing) has been used to establish the potential benefit of permanent pacemakers in patients with sinus bradycardia, first degree AV block, second degree AV block, and hypertrophic cardiomyopathy when the cause for symptoms is unclear. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7514?source=see_link&amp;anchor=H14#H14\">",
"       \"Nonpharmacologic treatment of outflow obstruction in hypertrophic cardiomyopathy\", section on 'Dual chamber pacing'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Temporary pacing in acute myocardial infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Temporary bradycardia pacing may be necessary in patients with an acute myocardial infarction, even when permanent pacing is not required [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21465/abstract/69-71\">",
"     69-71",
"    </a>",
"    ]. Revascularization strategies with thrombolysis and angioplasty have reduced the need for permanent pacing since there is less myocardial damage and a greater chance that bradycardia and conduction abnormalities will resolve. There may, however, be a need to temporary pacing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/11/4282?source=see_link\">",
"     \"Conduction abnormalities after myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An important consideration in the setting of an acute myocardial infarction is that a bradycardia, even if asymptomatic or transient, can cause decreased coronary blood flow and reduced myocardial perfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21465/abstract/72\">",
"     72",
"    </a>",
"    ]. Guidelines from the American Heart Association and American College of Cardiology recommend temporary bradycardia pacing in the following situations in patients with acute myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21465/abstract/73\">",
"     73",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Asystole",
"     </li>",
"     <li>",
"      Symptomatic bradycardia due to sinus node dysfunction or Mobitz type I second degree heart block that is not responsive to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"       atropine",
"      </a>",
"      therapy",
"     </li>",
"     <li>",
"      Mobitz type II second degree or complete AV block",
"     </li>",
"     <li>",
"      Bilateral or alternating bundle branch block including right bundle branch block with left anterior fascicular block or left posterior fascicular block",
"     </li>",
"     <li>",
"      A new bundle branch block with first degree AV block",
"     </li>",
"     <li>",
"      An old right bundle branch block with first degree AV block and a new fascicular block",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the potential benefit from the prophylactic use of an endocardial pacemaker for an asymptomatic conduction abnormality, its insertion is associated with some complications, especially in the patient who has received thrombolytic therapy and is being treated with aggressive anticoagulant and antiplatelet therapy. In these settings, external standby pacing may be appropriate, with the insertion of an endocardial pacemaker only if warranted because of the occurrence of symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Temporary pacing for permanent pacemaker or lead failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Temporary bradycardia pacing is indicated in patients who are pacemaker-dependent when a lead revision is necessary, during a pacemaker generator change, if the permanent pacemaker needs to be removed because of infection, or if there is a pacemaker or lead failure. In such situations, consideration must be given to a potential interaction between the permanent and temporary pacemaker. If, for example, the temporary pacemaker fails to capture but its output or pacing stimulus is sensed by the permanent pacemaker, the permanent pacemaker might be inhibited, resulting in a severe bradycardia or asystole.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Temporary pacing to prevent tachycardias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid temporary pacing can be used to prevent a tachycardia from occurring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Sick sinus syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a tachycardia-bradycardia syndrome, there is often an oscillation between rapid rates due to atrial fibrillation and slow rates due to sinus bradycardia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22008?source=see_link\">",
"     \"Manifestations and causes of the sick sinus syndrome\"",
"    </a>",
"    .) The slow sinus rates can result in atrial fibrillation as an escape arrhythmia; maintenance of a faster heart rate with pacing may prevent this.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     After cardiac surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overdrive pacing has been used after cardiac surgery to prevent atrial fibrillation and atrial flutter, although beta blockers are usually the treatment of choice. The potential efficacy of overdrive pacing was illustrated in a randomized of 96 patients undergoing coronary artery bypass graft surgery who were in sinus rhythm without antiarrhythmic drugs on the second postoperative day [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21465/abstract/74\">",
"     74",
"    </a>",
"    ]. Overdrive pacing for 24 hours significantly reduced the incidence of atrial fibrillation (10 versus 27 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28602?source=see_link\">",
"     \"Atrial fibrillation and flutter after cardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Ventricular tachyarrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some ventricular tachycardias can be prevented by rapid pacing. An example is torsades des pointes, a polymorphic ventricular tachycardia associated with a long QT interval. Atrial or ventricular pacing at rates between 90 and 110 beats per minute can prevent initiation of torsades des pointes by shortening the QT interval and by preventing ventricular premature beats that might trigger the tachycardia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26682?source=see_link\">",
"     \"Prognosis and management of congenital long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In some situations, ventricular fibrillation can be initiated during slow rates although the mechanism by which this happens is not well understood. Rapid atrial or ventricular overdrive pacing can decrease the risk of ventricular fibrillation, particularly in the postoperative period or when the ventricular arrhythmia results from an antiarrhythmic drug. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Prophylactic pacing prior to surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic pacing prior to noncardiac surgery is rarely indicated. However, temporary pacing can be useful for patients with complete heart block or symptomatic asystolic episodes who require nonelective cardiac surgery. Asymptomatic bifascicular block (eg, right bundle branch block and left anterior hemiblock) with or without first degree AV block, is not an indication for temporary endocardial pacing. However, the availability of an external pacer is appropriate and its use, which is rarely needed, is less risky.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Cardiac intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some clinicians advocate temporary pacing for \"high risk\" cardiac interventions, particularly a right coronary angioplasty, when AV block is present, or when there is a risk for the Bezold-Jarisch reflex.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Temporary dual chamber pacing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Temporary dual chamber pacing may be useful for patients who require AV sequential pacing for hemodynamic benefit. Included in this group are patients with an acute myocardial infarction, particularly when associated with right ventricular involvement; after cardiac surgery, especially when diastolic dysfunction is present; and patients with ventricular hypertrophy or a hypertrophic cardiomyopathy. Temporary dual chamber pacing can be used to assess the benefit of AV synchrony when permanent pacing is contemplated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Temporary biventricular pacing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac resynchronization therapy (CRT) with biventricular (BiV) pacing reduces heart failure (HF) symptoms and improves survival in patients with advanced HF, reduced left ventricular systolic function, and mechanical dyssynchrony. The chronic use of CRT via a permanently implanted biventricular pacemaker or an implantable cardioverter-defibrillator is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=see_link\">",
"     \"Cardiac resynchronization therapy in heart failure: Indications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Temporary BiV pacing with a transvenous pacing catheter placed in a coronary vein via the coronary sinus may provide short-term benefit to selected patients in cardiogenic shock [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21465/abstract/75\">",
"     75",
"    </a>",
"    ]. Response to this therapy may help to stabilize a patient and also determine the benefit of a permanent CRT device. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35418?source=see_link\">",
"     \"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Antitachycardia pacing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antitachycardia or overdrive pacing is a method to terminate a tachycardia by pacing at a rate faster than the tachycardia. Overdrive pacing may be helpful in the acute management of patients with frequent recurrent episodes, particularly when drug therapy is ineffective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Postoperative atrial flutter",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overdrive pacing is useful for patients undergoing cardiac surgery to pace-terminate atrial flutter that occurs intraoperatively or perioperatively. In some cases, purposeful rapid pacing of atrial flutter will precipitate atrial fibrillation that will allow better control of the ventricular response rate in the postoperative period. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/49/18201?source=see_link\">",
"     \"Restoration of sinus rhythm in atrial flutter\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Monomorphic ventricular tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overdrive pacing can terminate a repetitive monomorphic ventricular tachycardia until proper drug or ablative therapy can be instituted. This can be accomplished by endocardial or epicardial pacing. One commonly used method is to \"burst\" pace at progressively more rapid rates. When using overdrive pacing for ventricular tachycardia termination, backup defibrillation must be available since ventricular fibrillation can be provoked. In some cases, appropriately timed single, double, or triple ventricular extrastimuli are more effective to terminate the tachycardia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     WHEN TO AVOID TEMPORARY PACING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Temporary pacing should be avoided in the following settings.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When the risks outweigh the benefits.",
"     </li>",
"     <li>",
"      When there are intermittent, mild or rare symptoms and the bradycardia is well tolerated. This includes symptomatic complete heart block with an adequate and \"stable\" escape rhythm or symptomatic sick sinus syndrome with only rare pauses.",
"     </li>",
"     <li>",
"      In the presence of a prosthetic tricuspid valve or right ventricular infarct, a circumstance in which it may not be possible to achieve right ventricular capture.",
"     </li>",
"     <li>",
"      In a patient with a myocardial infarction who has received a thrombolytic agent and is being aggressively treated with anticoagulation or antiplatelet agents. Even insertion of the catheter by a cutdown of the right internal jugular vein may be associated with significant bleeding in such patients.",
"     </li>",
"     <li>",
"      When there is no informed consent unless temporary pacing is considered life-saving.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6611855\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Temporary cardiac pacing involves electrical cardiac stimulation to treat a tachyarrhythmia or bradyarrhythmia until it resolves or until long-term therapy can be initiated. Insertion of a temporary transvenous pacemaker lead should be performed only by those with appropriate expertise in the procedure and subsequent management of the pacemaker settings. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Technical skills'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most frequent use of temporary pacing is for therapy of symptomatic bradycardia due to either sinus node dysfunction or atrioventricular (AV) nodal block. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Modes of temporary cardiac pacing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The best access site for temporary pacing leads is via the left subclavian vein or the right internal jugular vein. Brachial and femoral approaches are not recommended because of the risk of cardiac puncture and instability using a brachial approach and the risk of deep vein thrombosis and infection using the femoral approach. Although the right internal jugular approach is usually preferred, the best approach to minimize complications is the one with which the clinician has the most experience. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Access site'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Epicardial pacing leads are often placed after cardiac surgery and can be used for temporary pacing if bradycardia occurs, or for overdrive pacing of a postoperative atrial tachyarrhythmia, especially atrial flutter. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Epicardial pacing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Large chest wall electrodes with a high impedance interface are required for external pacing. However, external pacing causes significant discomfort, and sedation or a state of unconsciousness are required to use this approach effectively for more than back-up or emergency pacing. Reliability limits its use, and it is often difficult to determine if there is adequate ventricular capture. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'External pacing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Continuous monitoring is mandatory during the entire time the patient has a temporary pacemaker, and a separate intravenous line or a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      lock is recommended should there be a need for drug therapy. Patients with temporary pacemakers require a daily check of pacing thresholds to make certain that there is proper capture and sensing. A chest X-ray should be obtained to determine the position of the endocardial leads. This test should be repeated if there is failure to capture or sense or a ventricular tachyarrhythmia occurs, which suggests electrode dislodgement. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Management of temporary pacemaker electrodes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In general, temporary pacing is indicated when a bradyarrhythmia causes severe hemodynamic impairment and when permanent pacing is not immediately indicated, not available, or the risk of inserting a permanent pacemaker exceeds potential benefit. Examples of situations in which temporary pacing is indicated include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Bradycardia resulting from an acute and potentially reversible condition (eg, post-cardiac surgery, Lyme disease, cardiac trauma, toxic or metabolic derangements, etc). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Temporary pacing for a reversible condition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bradycardia in the setting of an acute myocardial infarction, which is often reversible. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Temporary pacing in acute myocardial infarction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A pacemaker-dependent patient who is undergoing revision of",
"      <span class=\"nowrap\">",
"       his/her",
"      </span>",
"      permanent pacemaker system. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Temporary pacing for permanent pacemaker or lead failure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are certain rare occasions when temporary cardiac pacing may be contraindicated due to increased risks or lack of perceived benefit. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'When to avoid temporary pacing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/1\">",
"      Clinical competence in insertion of a temporary transvenous ventricular pacemaker. ACP/ACC/AHA Task Force on Clinical Privileges in Cardiology. J Am Coll Cardiol 1994; 23:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/2\">",
"      Francis GS, Williams SV, Achord JL, et al. Clinical competence in insertion of a temporary transvenous ventricular pacemaker. A statement for physicians from the ACP/ACC/AHA Task Force on Clinical Privileges in Cardiology. Circulation 1994; 89:1913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/3\">",
"      Davis GK, Roberts DH. Experience and training in temporary transvenous pacing. J R Coll Physicians Lond 1996; 30:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/4\">",
"      Murphy JJ, Frain JP, Stephenson CJ. Training and supervision of temporary transvenous pacemaker insertion. Br J Clin Pract 1995; 49:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/5\">",
"      Krueger SK, Rakes S, Wilkerson J, et al. Temporary pacemaking by general internists. Arch Intern Med 1983; 143:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/6\">",
"      Voigtl&auml;nder T, Nowak B, B&auml;renf&auml;nger P, et al. Feasibility and sensing thresholds of temporary single-lead VDD pacing in intensive care. Am J Cardiol 1997; 79:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/7\">",
"      Hildick-Smith DJ, Petch MC. Temporary pacing before permanent pacing should be avoided unless essential. BMJ 1998; 317:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/8\">",
"      Silver MD, Goldschlager N. Temporary transvenous cardiac pacing in the critical care setting. Chest 1988; 93:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/9\">",
"      Gillette PC. Antitachycardia pacing. Pacing Clin Electrophysiol 1997; 20:2121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/10\">",
"      Olshansky B, Okumura K, Hess PG, et al. Use of procainamide with rapid atrial pacing for successful conversion of atrial flutter to sinus rhythm. J Am Coll Cardiol 1988; 11:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/11\">",
"      Obel IW, Scott Millar RN. Temporary transvenous atrial pacing for the control of supraventricular tachycardia in the coronary care unit. Crit Care Med 1983; 11:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/12\">",
"      Waldo AL, Wells JL Jr, Cooper TB, MacLean WA. Temporary cardiac pacing: applications and techniques in the treatment of cardiac arrhythmias. Prog Cardiovasc Dis 1981; 23:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/13\">",
"      Greenberg ML, Kelly TA, Lerman BB, DiMarco JP. Atrial pacing for conversion of atrial flutter. Am J Cardiol 1986; 58:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/14\">",
"      Andersen HR, Pless P. Trans-esophageal pacing. Pacing Clin Electrophysiol 1983; 6:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/15\">",
"      Altamura G, Bianconi L, Toscano S, et al. Transcutaneous cardiac pacing for termination of tachyarrhythmias. Pacing Clin Electrophysiol 1990; 13:2026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/16\">",
"      Volkmann H, Dannberg G, Heinke M, K&uuml;hnert H. Termination of tachycardias by transesophageal electrical pacing. Pacing Clin Electrophysiol 1992; 15:1962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/17\">",
"      Ahern TS, Nydegger C, Greenspon AJ, et al. Programmable external automatic antitachycardia pacing as a bridge to definitive therapy in patients with recurrent sustained ventricular tachycardia. Pacing Clin Electrophysiol 1992; 15:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/18\">",
"      Wirtz S, Schulte HD, Winter J, et al. Reliability of different temporary myocardial pacing leads. Thorac Cardiovasc Surg 1989; 37:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/19\">",
"      Stefanadis C, Gavaliatsis I, Stratos C, et al. Temporary cardiac pacing using a new, steerable, balloon-tipped pacing catheter. Cathet Cardiovasc Diagn 1990; 21:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/20\">",
"      Ferguson JD, Banning AP, Bashir Y. Randomised trial of temporary cardiac pacing with semirigid and balloon-flotation electrode catheters. Lancet 1997; 349:1883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/21\">",
"      Lang R, David D, Klein HO, et al. The use of the balloon-tipped floating catheter in temporary transvenous cardiac pacing. Pacing Clin Electrophysiol 1981; 4:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/22\">",
"      Haffajee CI. Temporary cardiac pacing: modes, evaluation of function, equipment, and trouble shooting. Cardiol Clin 1985; 3:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/23\">",
"      Gould BA, Marshall AJ. Noninvasive temporary pacemakers. Pacing Clin Electrophysiol 1988; 11:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/24\">",
"      Jowett NI, Thompson DR, Pohl JE. Temporary transvenous cardiac pacing: 6 years experience in one coronary care unit. Postgrad Med J 1989; 65:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/25\">",
"      Schnitzler RN, Caracta AR, Damato AN. \"Floating\" catheter for temporary transvenous ventricular pacing. Am J Cardiol 1973; 31:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/26\">",
"      Dunn DL, Gregory JJ. Noninvasive temporary pacing: experience in a community hospital. Heart Lung 1989; 18:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/27\">",
"      Weinstein J, Gnoj J, Mazzara JT, et al. Temporary transvenous pacing via the percutaneous femoral vein approach. A prospective study of 100 cases. Am Heart J 1973; 85:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/28\">",
"      Littleford PO, Curry RC Jr, Schwartz KM, Pepine CJ. Clinical evaluation of a new temporary atrial pacing catheter: results in 100 patients. Am Heart J 1984; 107:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/29\">",
"      Samuels LE, Samuels FL, Kaufman MS, et al. Temporary epicardial atrial pacing electrodes: duration of effectiveness based on position. Am J Med Sci 1998; 315:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/30\">",
"      Del Nido P, Goldman BS. Temporary epicardial pacing after open heart surgery: complications and prevention. J Card Surg 1989; 4:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/31\">",
"      Ferguson TB Jr, Cox JL. Temporary external DDD pacing after cardiac operations. Ann Thorac Surg 1991; 51:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/32\">",
"      Falk RH, Zoll PM, Zoll RH. Safety and efficacy of noninvasive cardiac pacing. A preliminary report. N Engl J Med 1983; 309:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/33\">",
"      Zoll PM, Zoll RH, Falk RH, et al. External noninvasive temporary cardiac pacing: clinical trials. Circulation 1985; 71:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/34\">",
"      Luck JC, Markel ML. Clinical applications of external pacing: a renaissance? Pacing Clin Electrophysiol 1991; 14:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/35\">",
"      Rosenthal E, Thomas N, Quinn E, et al. Transcutaneous pacing for cardiac emergencies. Pacing Clin Electrophysiol 1988; 11:2160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/36\">",
"      Madsen JK, Meibom J, Videbak R, et al. Transcutaneous pacing: experience with the Zoll noninvasive temporary pacemaker. Am Heart J 1988; 116:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/37\">",
"      Little T. External cardiac pacing in right ventricular infarction. Ann Emerg Med 1988; 17:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/38\">",
"      Altamura G, Toscano S, Lo Bianco F, et al. Emergency cardiac pacing for severe bradycardia. Pacing Clin Electrophysiol 1990; 13:2038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/39\">",
"      Barthell E, Troiano P, Olson D, et al. Prehospital external cardiac pacing: a prospective, controlled clinical trial. Ann Emerg Med 1988; 17:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/40\">",
"      Benson DW Jr. Transesophageal electrocardiography and cardiac pacing: state of the art. Circulation 1987; 75:III86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/41\">",
"      Gallagher JJ, Smith WM, Kerr CR, et al. Esophageal pacing: a diagnostic and therapeutic tool. Circulation 1982; 65:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/42\">",
"      Baciewicz FA Jr, Leighton RF, Davis JT. Use of rapid atrial pacing to induce 2:1 atrioventricular block with marked improvement in hemodynamics. Int J Cardiol 1987; 17:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/43\">",
"      Hartzler GO, Maloney JD, Curtis JJ, Barnhorst DA. Hemodynamic benefits of atrioventricular sequential pacing after cardiac surgery. Am J Cardiol 1977; 40:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/44\">",
"      Sheron N, Clarke M. Temporary sequential atrioventricular pacing in myocardial infarction. Postgrad Med J 1987; 63:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/45\">",
"      Topol EJ, Goldschlager N, Ports TA, et al. Hemodynamic benefit of atrial pacing in right ventricular myocardial infarction. Ann Intern Med 1982; 96:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/46\">",
"      Wish M, Fletcher RD, et al. Hemodynamics of AV synchrony and rate. J Electrophysiol 1989; 3:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/47\">",
"      Littleford PO, Schwartz KM, Pepine CJ. A temporary external DDD pacing unit. Am J Cardiol 1984; 53:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/48\">",
"      Scott WA, Lemler M, Farley L, Zehr R. Evaluation of temporary atrial pacing leads. Pacing Clin Electrophysiol 1993; 16:1789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/49\">",
"      Takeda M, Furuse A, Kotsuka Y. Use of temporary atrial pacing in management of patients after cardiac surgery. Cardiovasc Surg 1996; 4:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/50\">",
"      Ohm OJ, Breivik K, Segadal L, Engedal H. New temporary atrial and ventricular pacing leads for patients after cardiac operations. J Thorac Cardiovasc Surg 1995; 110:1725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/51\">",
"      Moreira DA, Shepard RB, Waldo AL. Chronic rapid atrial pacing to maintain atrial fibrillation: use to permit control of ventricular rate in order to treat tachycardia induced cardiomyopathy. Pacing Clin Electrophysiol 1989; 12:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/52\">",
"      Bing OH, McDowell JW, Hantman J, Messer JV. Pacemaker placement by electrocardiographic monitoring. N Engl J Med 1972; 287:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/53\">",
"      Brown CG, Hutchins GM, Gurley HT, et al. Placement accuracy of percutaneous transthoracic pacemakers. Am J Emerg Med 1985; 3:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/54\">",
"      Evans GL, Glasser SP. Intracavitary electrocardiography as a guide to pacemaker postitioning. JAMA 1971; 216:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/55\">",
"      Ezeugwu CO, Oropello JM, Pasik AS, Benjamin E. Position of temporary transvenous pacemaker after insertion. J Cardiothorac Vasc Anesth 1994; 8:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/56\">",
"      Goldberger J, Kruse J, Ehlert FA, Kadish A. Temporary transvenous pacemaker placement: what criteria constitute an adequate pacing site? Am Heart J 1993; 126:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/57\">",
"      Rubenfire M, Melean J, Conrad E. Pseudoarrhythmia caused by temporary transvenous pacemaker. JAMA 1976; 235:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/58\">",
"      Bedynek JL Jr. Editorial: Temporary transvenous cardiac pacing--be careful. Am Fam Physician 1975; 11:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/59\">",
"      Reddy SC, Saxena A, Iyer KS. Inadvertent but asymptomatic right atrial perforation with epicardial pacing in a neonate: a rare complication of temporary transvenous cardiac pacing. Pacing Clin Electrophysiol 1997; 20:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/60\">",
"      Austin JL, Preis LK, Crampton RS, et al. Analysis of pacemaker malfunction and complications of temporary pacing in the coronary care unit. Am J Cardiol 1982; 49:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/61\">",
"      Hill PE. Complications of permanent transvenous cardiac pacing: a 14-year review of all transvenous pacemakers inserted at one community hospital. Pacing Clin Electrophysiol 1987; 10:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/62\">",
"      Murphy JJ. Current practice and complications of temporary transvenous cardiac pacing. BMJ 1996; 312:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/63\">",
"      Nolewajka AJ, Goddard MD, Brown TC. Temporary transvenous pacing and femoral vein thrombosis. Circulation 1980; 62:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/64\">",
"      McLeod AA, Jokhi PP. Pacemaker induced ventricular fibrillation in coronary care units. BMJ 2004; 328:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/65\">",
"      Trigano AJ, Azoulay A, Rochdi M, Campillo A. Electromagnetic interference of external pacemakers by walkie-talkies and digital cellular phones: experimental study. Pacing Clin Electrophysiol 1999; 22:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/66\">",
"      Del Negro AA, Fletcher RD. Indications for and use of artificial cardiac pacemakers: Part II. Curr Probl Cardiol 1978; 3:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/67\">",
"      DeGuzman M, Rahimtoola SH. What is the role of pacemakers in patients with coronary artery disease and conduction abnormalities? Cardiovasc Clin 1983; 13:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/68\">",
"      Gilchrist IC, Cameron A. Chronic bundle branch block and use of temporary transvenous pacemakers during coronary arteriography. Cathet Cardiovasc Diagn 1988; 15:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/69\">",
"      Hindman MC, Wagner GS, JaRo M, et al. The clinical significance of bundle branch block complicating acute myocardial infarction. 2. Indications for temporary and permanent pacemaker insertion. Circulation 1978; 58:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/70\">",
"      Rosenfeld LE. Bradyarrhythmias, abnormalities of conduction, and indications for pacing in acute myocardial infarction. Cardiol Clin 1988; 6:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/71\">",
"      Berger PB, Ruocco NA Jr, Ryan TJ, et al. Incidence and prognostic implications of heart block complicating inferior myocardial infarction treated with thrombolytic therapy: results from TIMI II. J Am Coll Cardiol 1992; 20:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/72\">",
"      Johnson LW, Bowser MA, Lozner EC. Use of temporary pacemakers during coronary angioplasty: an evolving experience with ventricular fibrillation in 400 cases. Cathet Cardiovasc Diagn 1988; 15:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/73\">",
"      Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004; 110:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/74\">",
"      Blommaert D, Gonzalez M, Mucumbitsi J, et al. Effective prevention of atrial fibrillation by continuous atrial overdrive pacing after coronary artery bypass surgery. J Am Coll Cardiol 2000; 35:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21465/abstract/75\">",
"      Guo H, Hahn D, Olshansky B. Temporary biventricular pacing in a patient with subacute myocardial infarction, cardiogenic shock, and third-degree atrioventricular block. Heart Rhythm 2005; 2:112.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1005 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-89.218.100.194-DA315AB02B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_61_21465=[""].join("\n");
var outline_f20_61_21465=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6611855\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TECHNICAL SKILLS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MODES OF TEMPORARY CARDIAC PACING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      APPROACHES TO TEMPORARY PACING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Types of electrode catheters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Insertion techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Access site",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Lead placement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Pacemaker system",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Transesophageal pacing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Epicardial pacing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - External pacing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Management of temporary pacemaker electrodes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Electromagnetic interference",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Temporary pacing for a reversible condition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Temporary pacing in acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Temporary pacing for permanent pacemaker or lead failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Temporary pacing to prevent tachycardias",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Sick sinus syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - After cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Ventricular tachyarrhythmias",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Prophylactic pacing prior to surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Cardiac intervention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Temporary dual chamber pacing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Temporary biventricular pacing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Antitachycardia pacing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Postoperative atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Monomorphic ventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      WHEN TO AVOID TEMPORARY PACING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6611855\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1005\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1005|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/46/1772\" title=\"table 1A\">",
"      NBG code pacing nomenclature",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/27/28091\" title=\"table 1B\">",
"      Ventricular and atrial pacers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/58/5036\" title=\"table 2\">",
"      Transcutaneous pacemaker indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/37/11868\" title=\"table 3\">",
"      Temporary transvenous pacing indications",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/1/23576?source=related_link\">",
"      Arrhythmias following cardiac transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28602?source=related_link\">",
"      Atrial fibrillation and flutter after cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24793?source=related_link\">",
"      Atrioventricular nodal reentrant tachycardia (junctional reciprocating tachycardia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28072?source=related_link\">",
"      Basic approach to arrhythmias due to digoxin toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/56/11142?source=related_link\">",
"      Cardiac device interactions with electromagnetic fields",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=related_link\">",
"      Cardiac resynchronization therapy in heart failure: Indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33882?source=related_link\">",
"      Causes and evaluation of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/11/4282?source=related_link\">",
"      Conduction abnormalities after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24408?source=related_link\">",
"      Control of ventricular rate in atrial fibrillation: Nonpharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35226?source=related_link\">",
"      Early noncardiac complications of coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27463?source=related_link\">",
"      Indications for permanent cardiac pacing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25221?source=related_link\">",
"      Insertion of pulmonary artery catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40759?source=related_link\">",
"      Lyme carditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3704?source=related_link\">",
"      Major side effects of beta blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22008?source=related_link\">",
"      Manifestations and causes of the sick sinus syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1849?source=related_link\">",
"      Modes of cardiac pacing: Nomenclature and selection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7514?source=related_link\">",
"      Nonpharmacologic treatment of outflow obstruction in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26682?source=related_link\">",
"      Prognosis and management of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35418?source=related_link\">",
"      Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27128?source=related_link\">",
"      Pulmonary artery catheterization: Indications and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/49/18201?source=related_link\">",
"      Restoration of sinus rhythm in atrial flutter",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_61_21466="Clinical applications of thrombopoietic growth factors";
var content_f20_61_21466=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical applications of thrombopoietic growth factors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/61/21466/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/61/21466/contributors\">",
"     David J Kuter, MD, DPhil",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/61/21466/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/61/21466/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/61/21466/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/61/21466/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/61/21466/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 30, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of hematopoietic growth factors has markedly changed the practice of medicine. Erythroid (eg, erythropoietin, darbepoetin) and myeloid (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    , granulocyte-macrophage colony-stimulating factor) growth factors have allowed the specific stimulation of the production of erythrocytes and neutrophils, respectively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/31/16890?source=see_link\">",
"     \"Introduction to recombinant hematopoietic growth factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With the discovery of thrombopoietin (TPO) and the development of a variety of peptide and non-peptide TPO receptor agonists (TPO mimetics), clinically effective thrombopoietic growth factors have now entered the clinical armamentarium. This topic review will discuss the thrombopoietins and TPO receptor agonists that have been developed, their activity in preclinical models, and the available clinical studies. The biology of TPO is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16680?source=see_link\">",
"     \"Biology and physiology of thrombopoietin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6974285\">",
"    <span class=\"h1\">",
"     CLINICAL UTILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential clinical applications of thrombopoietic growth factors are suggested by analyzing the use of platelet transfusions (",
"    <a class=\"graphic graphic_figure graphicRef77264 \" href=\"UTD.htm?5/13/5343\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20586?source=see_link&amp;anchor=H558384432#H558384432\">",
"     \"Clinical and laboratory aspects of platelet transfusion therapy\", section on 'Indications for platelet transfusion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two thrombopoietic growth factors have been approved for the treatment of chronic immune thrombocytopenia (chronic ITP). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39322?source=see_link&amp;anchor=H21#H21\">",
"     \"Treatment and prognosis of immune (idiopathic) thrombocytopenic purpura in adults\", section on 'Thrombopoiesis-stimulating agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The utility of these agents in myelodysplastic syndromes is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/54/25450?source=see_link&amp;anchor=H2104265#H2104265\">",
"     \"Management of the complications of the myelodysplastic syndromes\", section on 'Thrombopoietin mimetics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are numerous other potential uses of these agents. (See",
"    <a class=\"local\" href=\"#H9580690\">",
"     'Other potential uses of TPO receptor agonists'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H18\">",
"     'Use of TPO receptor agonists'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H27\">",
"     'Transfusion medicine'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     THROMBOPOIETINS (C-MPL LIGANDS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of thrombopoietin molecules have been developed; they define a new and growing family of molecules called the thrombopoietin (or mpl ligand) family, based upon their common ability to bind and activate the thrombopoietin (TPO) receptor, c-mpl [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/1\">",
"     1",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef55953 \" href=\"UTD.htm?21/44/22219\">",
"     table 1",
"    </a>",
"    ). These include the recombinant thrombopoietins and two different types of TPO receptor agonists (also called TPO mimetics): peptide TPO receptor agonists and non-peptide TPO receptor agonists [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/2\">",
"     2",
"    </a>",
"    ]. These molecules are functional rather than structural TPO mimetics, because they act as agonists for the TPO receptor but lack sequence homology to the TPO protein.",
"   </p>",
"   <p>",
"    There have been two waves of development of thrombopoietins; the first generation molecules were recombinant thrombopoietins (eg, rHuTPO, PEG-rHuMGDF) that are no longer being developed. The second generation molecules are highly modified structures (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/58/20389?source=see_link\">",
"     romiplostim",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/17/11543?source=see_link\">",
"     eltrombopag",
"    </a>",
"    ) that mimic the function of TPO, both of which are now FDA-approved for the treatment of chronic ITP and have entered clinical practice [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Recombinant thrombopoietins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two recombinant thrombopoietins were subjected to intensive clinical investigation (",
"    <a class=\"graphic graphic_figure graphicRef58678 \" href=\"UTD.htm?0/48/783\">",
"     figure 2",
"    </a>",
"    ). Although no longer under development, they illustrate the general clinical effects of all the thrombopoietins [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recombinant human thrombopoietin (rHuTPO) is a glycosylated molecule produced in CHO cells consisting of the full-length, native human amino acid sequence, which has a circulatory half-life of 20 to 40 hours. In one report, a single dose of rHuTPO produced an increase in platelet count that began by day five in most patients and peaked at a mean of day 12 [",
"      <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pegylated, recombinant megakaryocyte growth and development factor (PEG-rHuMGDF), a nonglycosylated, truncated molecule produced in Escherichia coli, is composed of the first 163 amino acids of the native molecule, chemically coupled to polyethylene glycol. This half of the native molecule is 50 percent similar to erythropoietin, contains the receptor-binding domain, but has a very short circulatory half-life and no biologic activity in vivo due to the absence of the remaining, carbohydrate-rich portion of the native molecule. Addition of the polyethylene glycol moiety serves to replace the missing carbohydrate domain and stabilize the molecule in the circulation. PEG-rHuMGDF has a half-life of 30 to 40 hours. Clinical development of this molecule was stopped because of the development of antibodies, leading to thrombocytopenia, in approximately 8 percent of subjects (see",
"      <a class=\"local\" href=\"#H33\">",
"       'Antibody formation'",
"      </a>",
"      below) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/1,6\">",
"       1,6",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16680?source=see_link\">",
"       \"Biology and physiology of thrombopoietin\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Peptide thrombopoietin receptor agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peptide TPO receptor agonists are short peptide sequences, usually with no sequence homology with TPO, that bind and activate the TPO receptor. They were discovered by screening peptide \"libraries\" for sequences that activated the TPO receptor. One of these was a 14-amino acid peptide having no sequence homology with thrombopoietin, which was able to bind to and activate the thrombopoietin receptor, c-mpl [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/7\">",
"     7",
"    </a>",
"    ]. Dimerization of this peptide increased its activity 10,000-fold, thereby making it as active as recombinant TPO.",
"   </p>",
"   <p>",
"    A key attribute of all of the peptide TPO receptor agonists is the need for a structure that allows them to dimerize and activate the thrombopoietin receptor. These peptides have too short a half-life in the circulation to be clinically active. To enhance their circulatory half-life, such peptides have been inserted into an immunoglobulin heavy chain construct (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/58/20389?source=see_link\">",
"     romiplostim",
"    </a>",
"    ); this construct (called a &ldquo;peptibody&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/8\">",
"     8",
"    </a>",
"    ]) has marked clinical activity. These molecules are administered subcutaneously or intravenously.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Romiplostim (AMG 531, Nplate)",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/58/20389?source=see_link\">",
"     Romiplostim",
"    </a>",
"    is a \"peptibody\" composed of two disulphide-bonded human IgG1 kappa heavy chain constant regions (an Fc fragment), each of which is covalently bound at residue 228 with two identical peptide sequences linked via polyglycine (",
"    <a class=\"graphic graphic_figure graphicRef69951 \" href=\"UTD.htm?4/62/5103\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/8\">",
"     8",
"    </a>",
"    ]. This agent increased the platelet count in healthy individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/9,10\">",
"     9,10",
"    </a>",
"    ] as well as in patients with immune thrombocytopenic purpura (ITP) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/11-13\">",
"     11-13",
"    </a>",
"    ], and myelodysplastic syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. Romiplostim is also being evaluated in patients with chemotherapy-induced thrombocytopenia and hepatitis C-related thrombocytopenia. It is currently only FDA-approved for the treatment of chronic ITP in adults and is administered weekly as a subcutaneous injection at a dose of 1 to 10",
"    <span class=\"nowrap\">",
"     mcg/kg.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29194?source=see_link&amp;anchor=H7#H7\">",
"     \"Chronic refractory immune (idiopathic) thrombocytopenic purpura in adults\", section on 'Romiplostim'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Non-peptide TPO receptor agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-peptide TPO receptor agonists were derived from small molecule screening techniques that uncovered a large number of chemical structures that bound to and activated the TPO receptor. Structures such as the hydrazinonaphthalene compounds readily activate the thrombopoietin receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. A number of these are in clinical development and one,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/17/11543?source=see_link\">",
"     eltrombopag",
"    </a>",
"    , has been FDA-approved for the treatment of chronic ITP. One potential advantage they have over the peptide TPO receptor agonists is that they may be administered orally. Many of these molecules bind to and activate the TPO receptor by a mechanism different from endogenous TPO, recombinant TPO, or the peptide TPO receptor agonists [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/3\">",
"     3",
"    </a>",
"    ]. Their effect is therefore additive to that of TPO and this may confer on them a second advantage over peptide TPO receptor agonists.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Eltrombopag (SB497115, Promacta/Revolade)",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/17/11543?source=see_link\">",
"     Eltrombopag",
"    </a>",
"    <span class=\"nowrap\">",
"     (Promacta/Revolade)",
"    </span>",
"    has an acidic (COOH) group at one end, lipophilic (eg, methyl) groups at the other end, and a metal chelate group in the center that creates a potent, orally available non-peptide TPO receptor agonist (",
"    <a class=\"graphic graphic_figure graphicRef79697 \" href=\"UTD.htm?19/8/19584\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/20\">",
"     20",
"    </a>",
"    ]. It increases the platelet count in healthy individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/17,21\">",
"     17,21",
"    </a>",
"    ] and in patients with ITP [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/22-24\">",
"     22-24",
"    </a>",
"    ] or thrombocytopenia due to hepatitis C [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/25\">",
"     25",
"    </a>",
"    ]. In one small trial there was no effect on platelet count nadir or platelet transfusions when administered to patients after non-myeloablative chemotherapy. It is FDA-approved only for the treatment of adults with ITP and is administered orally at a dose of 25 to 75 mg per day (lower doses in patients of Asian ancestry).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     E5501 (formerly AKR-501 and YM 477)",
"    </span>",
"    &nbsp;&mdash;&nbsp;E5501 is a second orally active non-peptide TPO receptor agonist identified through screening of small molecule libraries for the ability to activate a reporter molecule in TPO-dependent cell lines [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Active compounds were initially identified and then optimized for their biological effect and pharmaceutical properties. Unlike",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/17/11543?source=see_link\">",
"     eltrombopag",
"    </a>",
"    , absorption of E5501 is not affected by food and is not associated with liver function test abnormalities. E5501 increased the platelet count in healthy subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/28\">",
"     28",
"    </a>",
"    ] and patients with ITP. Additional studies in ITP, liver disease, and patients receiving chemotherapy are being considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     OTHER THROMBOPOIETIC GROWTH FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since they are based on the only physiologically relevant platelet growth factor, thrombopoietin, the thrombopoietins (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Thrombopoietins (c-mpl ligands)'",
"    </a>",
"    above) have captured most of the attention. However, several other thrombopoietic growth factors not related to thrombopoietin or its receptor have been developed. One has been FDA approved for use, and the rest are no longer being developed. In general, they have rather modest thrombopoietic activity and too many adverse consequences to be used widely.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Interleukins",
"    </span>",
"    &nbsp;&mdash;&nbsp;IL-3, IL-6, and IL-11 produce significant stimulation of platelet production. IL-3 and IL-6 are probably too toxic for most clinical uses, but recombinant IL-11 has been approved by the United States Food and Drug Administration for use in the prevention of chemotherapy-induced thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Oprelvekin (IL-11, Neumega)",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/58/34724?source=see_link\">",
"     Oprelvekin",
"    </a>",
"    stimulates megakaryocyte growth in vitro and increases platelet production in vivo with a time course similar to that of thrombopoietin. Its thrombopoietic action is not mediated through thrombopoietin release or synergism, and is independent of the thrombopoietin receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/30\">",
"     30",
"    </a>",
"    ]. IL-11 is probably not important for normal megakaryocytopoiesis, since elimination of the gene for the IL-11 receptor in mice produced no effect on the production of platelets or any other blood cell line [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In clinical studies, IL-11 (at a dose of 50",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    daily) has modestly reduced the extent of chemotherapy-induced thrombocytopenia and the need for platelet transfusions [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/3,32-35\">",
"     3,32-35",
"    </a>",
"    ]. Major side effects include fluid retention with dilutional anemia, peripheral edema, pleural effusions, and atrial arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/3,32\">",
"     3,32",
"    </a>",
"    ]. Papilledema has been described in children receiving high doses of this agent (100",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per day) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/33\">",
"     33",
"    </a>",
"    ]. Given its many adverse effects, use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/58/34724?source=see_link\">",
"     oprelvekin",
"    </a>",
"    is rarely justified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     USE OF TPO RECEPTOR AGONISTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombocytopenia is a common problem in many chronic hematologic conditions, ranging from aplastic anemia to drug-induced thrombocytopenia. Although only a few human studies have been reported, it is anticipated that, if adequate amounts of responsive precursor cells are present, thrombopoietin may be helpful in many of these patients. Preclinical and early clinical data provide some guidance as to the settings in which the thrombopoietins may or may not be useful [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/3,36\">",
"     3,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6974564\">",
"    <span class=\"h2\">",
"     Immune thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The finding that thrombopoietin levels in patients with immune thrombocytopenia (ITP) were not significantly elevated [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/37,38\">",
"     37,38",
"    </a>",
"    ] and that most patients with ITP are not producing platelets at a maximal rate [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/33,39\">",
"     33,39",
"    </a>",
"    ], suggests a potential benefit of thrombopoietin in this disorder. Two early studies have been reported on this application:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One patient with a variant of ITP characterized by cyclic thrombocytopenia and anti-platelet antibodies had been treated for over six years with frequent injections of PEG-rHuMGDF and has maintained an adequate platelet count [",
"      <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Three of four Japanese patients treated with PEG-rHuMGDF daily for up to seven days had their platelet count rise into the normal range. These responses were temporary; platelet counts returned to baseline in all subjects within four to six weeks following the last injection [",
"      <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While PEG-rHuMGDF is no longer available,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/58/20389?source=see_link\">",
"     romiplostim",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/17/11543?source=see_link\">",
"     eltrombopag",
"    </a>",
"    are now FDA-approved for treating adults with ITP and have been found to be highly effective [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/11-13,23\">",
"     11-13,23",
"    </a>",
"    ]. In general, over 80 percent of ITP patients treated with TPO receptor agonists attain a long term rise in platelet count &gt;50,000 with reduced bleeding, increased quality of life, and minimal adverse effects (",
"    <a class=\"graphic graphic_table graphicRef55815 \" href=\"UTD.htm?19/54/20331\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/42\">",
"     42",
"    </a>",
"    ]. This subject is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29194?source=see_link&amp;anchor=H5#H5\">",
"     \"Chronic refractory immune (idiopathic) thrombocytopenic purpura in adults\", section on 'Thrombopoiesis-stimulating agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Myelodysplastic syndromes and aplastic anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone marrow from some patients with myelodysplastic syndrome (MDS), acute myeloid leukemia, and aplastic anemia can be stimulated in vitro to form megakaryocytes, suggesting that some patients with these disorders might benefit from administration of TPO [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/43\">",
"     43",
"    </a>",
"    ]. In one study of 21 patients, treatment with PEG-rHuMGDF doubled the platelet count after five weeks of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/44\">",
"     44",
"    </a>",
"    ]. One subject with MDS was treated for over 450 days; while the platelet count rose from",
"    <span class=\"nowrap\">",
"     &lt;10,000/microL",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     50,000/microL,",
"    </span>",
"    there was a multilineage effect seen with the hemoglobin rising to &gt;13",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/58/20389?source=see_link\">",
"     romiplostim",
"    </a>",
"    treatment increased the platelet count and reduced the need for platelet transfusions in patients with MDS receiving supportive care only [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/14,15\">",
"     14,15",
"    </a>",
"    ] or chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/16\">",
"     16",
"    </a>",
"    ]. However, trials of romiplostim in MDS have been stopped due to safety concerns. The use of romiplostim in patients with MDS is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/54/25450?source=see_link&amp;anchor=H2104265#H2104265\">",
"     \"Management of the complications of the myelodysplastic syndromes\", section on 'Thrombopoietin mimetics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     HIV-associated thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;This subject is discussed separately. In the only available study, all six thrombocytopenic HIV patients treated with PEG-rHuMGDF normalized their platelet count [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/45\">",
"     45",
"    </a>",
"    ]. Although unreported with TPO receptor agonists, this author has found modest platelet count increases in three HIV-infected patients with platelet counts &lt;10,000 after treatment with TPO receptor agonists. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14522?source=see_link&amp;anchor=H18#H18\">",
"     \"Hematologic manifestations of HIV infection: Thrombocytopenia and coagulation abnormalities\", section on 'Thrombopoietic growth factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Liver disease",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H558386947\">",
"    <span class=\"h3\">",
"     Rationale",
"    </span>",
"    &nbsp;&mdash;&nbsp;The thrombocytopenia seen in liver disease is due to two general mechanisms. The first is an immune thrombocytopenia (ITP)-like process that is commonly seen in patients with chronic HCV infection, and commonly responds to the standard ITP treatments. The other mechanism of thrombocytopenia is due to reduced TPO production by a damaged liver. Studies of liver transplantation have shown that thrombopoietin levels are often undetectable pre-transplantation and rise immediately post-transplantation, followed by a rise in peripheral platelet count [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Chronic HCV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/17/11543?source=see_link\">",
"     Eltrombopag",
"    </a>",
"    has been shown to be effective in raising the platelet count in a series of 74 patients with chronic hepatitis C virus infection and platelet counts in the range of 20,000 to",
"    <span class=\"nowrap\">",
"     70,000/microL.",
"    </span>",
"    Patients were treated for four weeks with placebo or eltrombopag at doses of 30, 50, or 75",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    daily in a blinded, randomized phase II study [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/25\">",
"     25",
"    </a>",
"    ]. The median platelet count for the four groups at week 4 was 53,000, 137,000, 214,000, and",
"    <span class=\"nowrap\">",
"     209,000/microL,",
"    </span>",
"    respectively, with zero, 75, 79, and 95 percent having platelets",
"    <span class=\"nowrap\">",
"     &ge;100,000/microL.",
"    </span>",
"    None of the patients with liver disease had worsening of their liver function tests. Patients were subsequently eligible to undergo interferon treatment along with the eltrombopag; 12 weeks of such therapy were successfully completed by 6, 36, 53, and 65 percent of the four groups of subjects, respectively. Phase III studies testing the use of eltrombopag to improve platelet count enough to permit patients with hepatitis C to receive disease-modifying therapy are underway.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H558387015\">",
"    <span class=\"h3\">",
"     Advanced liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a randomized trial, administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/17/11543?source=see_link\">",
"     eltrombopag",
"    </a>",
"    to patients with advanced chronic liver disease and cirrhosis raised platelet counts and reduced the need for platelet transfusions prior to invasive procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/48\">",
"     48",
"    </a>",
"    ]. However, this was associated with an increase in portal vein thrombosis, resulting in premature termination of the trial. Given the high rate of asymptomatic portal vein thrombosis in this patient population, the failure to determine the pretreatment rate of thrombosis is a major limitation of this study. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33914?source=see_link\">",
"     \"Coagulation abnormalities in patients with liver disease\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H32\">",
"     'Side effects and risks'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Thrombocytopenia with absent radius syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The low platelet count in patients with the thrombocytopenia with absent radius (TAR) syndrome appears to result from failure of cell signaling events downstream from the thrombopoietin receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/49\">",
"     49",
"    </a>",
"    ]. It is thus unlikely that exogenous thrombopoietin will be useful in this disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14490?source=see_link&amp;anchor=H28#H28\">",
"     \"Neonatal thrombocytopenia\", section on 'Thrombocytopenia-absent radius syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Congenital amegakaryocytic thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with congenital amegakaryocytic thrombocytopenia (CAMT) have mutations in the TPO receptor that make them unresponsive to TPO [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. They present with thrombocytopenia at birth and subsequently develop pancytopenia. In vitro, a few respond to recombinant TPO but most do not. However, a new monoclonal antibody (\"minibody\") binds the TPO receptor in a way different from TPO and has been shown in vitro to activate the mutated receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/52\">",
"     52",
"    </a>",
"    ]. However, no clinical studies have been conducted to confirm this finding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1731175\">",
"    <span class=\"h2\">",
"     MYH9-related congenital thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of the congenital thrombocytopenias, non-muscle heavy-chain myosin-9 (MYH9)-related thrombocytopenias are associated with a number of distinct clinical syndromes and mutations in MYH9 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/53\">",
"     53",
"    </a>",
"    ]. Although most have mild thrombocytopenia with minimal bleeding, some have more severe thrombocytopenia with associated increased risk for bleeding. In one study, 12 adults with MYH9-related thrombocytopenia (platelets &lt;50,000) were treated with 50 mg daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/17/11543?source=see_link\">",
"     eltrombopag",
"    </a>",
"    for at least three weeks. In eight patients the platelet count either rose above 100,000 or three times baseline; three patients doubled their baseline platelet count; only one patient failed to respond [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/54\">",
"     54",
"    </a>",
"    ]. Bleeding decreased in 8 of 10 subjects with baseline bleeding. Only two patients had mild adverse events. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/9/29850?source=see_link&amp;anchor=H27#H27\">",
"     \"Congenital and acquired disorders of platelet function\", section on 'Giant platelet disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9580690\">",
"    <span class=\"h1\">",
"     OTHER POTENTIAL USES OF TPO RECEPTOR AGONISTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Except for immune thrombocytopenia (ITP), hepatitis C thrombocytopenia, and myelodysplastic syndrome (MDS), there have been no controlled studies reporting the use of either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/58/20389?source=see_link\">",
"     romiplostim",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/17/11543?source=see_link\">",
"     eltrombopag",
"    </a>",
"    in most thrombocytopenic disorders. There are data on the use of the earlier recombinant TPO agents (rHuTPO and PEG-rHuMGDF), as follows:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9580743\">",
"    <span class=\"h2\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemotherapy patients use approximately 25 percent of all platelet products transfused in the United States. This is a major area in which thrombopoietins might show benefit in the primary or secondary prophylaxis of thrombocytopenia. In several animal models of radiation- and chemotherapy-induced thrombocytopenia, administration of recombinant thrombopoietins was associated with a slightly earlier platelet nadir, shorter duration of thrombocytopenia, and, in some models, a reduction in the depth of the platelet nadir (",
"    <a class=\"graphic graphic_figure graphicRef82447 \" href=\"UTD.htm?31/17/32030\">",
"     figure 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/55\">",
"     55",
"    </a>",
"    ]. The duration of neutropenia and anemia was also shortened in some cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9580750\">",
"    <span class=\"h3\">",
"     Solid tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the administration of recombinant TPO to humans undergoing non-myeloablative chemotherapy, platelet recovery was enhanced but, unlike the animal models, with no change in the recovery of white or red blood cells.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study, for example, evaluated 53 patients with lung cancer treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/56\">",
"       56",
"      </a>",
"      ]. Thirty-eight received doses of PEG-rHuMGDF ranging from 0.03 to 5",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      daily after chemotherapy and 15 received placebo. Patients who received PEG-rHuMGDF had a significantly higher platelet nadir than those treated with placebo (188,000 versus",
"      <span class=\"nowrap\">",
"       111,000/microL)",
"      </span>",
"      and an earlier return of their platelet counts to baseline (14 versus 21 days) (",
"      <a class=\"graphic graphic_figure graphicRef74521 \" href=\"UTD.htm?2/0/2062\">",
"       figure 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In a second trial, 41 cancer patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      were randomly assigned to receive either PEG-rHuMGDF or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/57\">",
"       57",
"      </a>",
"      ]. There was no effect on the platelet nadir although the patients who received PEG-rHuMGDF had an earlier return of their platelet counts to baseline (17 versus 22 days).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although these studies demonstrated that thrombopoietin has activity in the chemotherapy setting and is safe, as no adverse events were attributed to the PEG-rHuMGDF, they were not intended to reduce the need for platelet transfusions. Few of the patients received platelet transfusions because the dose intensity of the chemotherapy was not high enough. However, in a third trial using a dose-intense chemotherapy regimen to treat patients with ovarian cancer, rHuTPO elevated nadir platelet counts, reduced the duration of thrombocytopenia, along with an over 50 percent reduction in the need for platelet transfusions (",
"    <a class=\"graphic graphic_figure graphicRef77335 \" href=\"UTD.htm?7/52/8014\">",
"     figure 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is not clear if eliminating treatment delays by using thrombopoietic agents and thereby maintaining the dose intensity of ICE chemotherapy would translate into better clinical outcomes. A randomized, double-blind, placebo controlled phase",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    trial of PEG-rHuMGDF in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     filgrastim",
"    </a>",
"    studied 38 patients with relapsed, refractory aggressive NHL who were given ICE chemotherapy for stem cell mobilization prior to autologous hematopoietic cell transplantation with the following results [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/59\">",
"     59",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients given PEG-rHuMGDF had significantly less grade IV thrombocytopenia (35 versus 15 percent) and a significantly higher median nadir platelet count",
"      <span class=\"nowrap\">",
"       (49,000/microL",
"      </span>",
"      versus",
"      <span class=\"nowrap\">",
"       20,000/microL)",
"      </span>",
"      compared with those given placebo.",
"     </li>",
"     <li>",
"      Patients given PEG-rHuMGDF were more likely to receive ICE on schedule (77 versus 44 percent).",
"     </li>",
"     <li>",
"      For patients who went on to receive HCT, overall survival was significantly higher in those who received their therapy on schedule compared with those whose therapy was delayed (73 versus 13 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the development of PEG-rHuMGDF has been abandoned due to a high incidence of antibody development leading to thrombocytopenia, further investigation of the current TPO receptor agonists may be warranted in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9580757\">",
"    <span class=\"h3\">",
"     Acute leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to non-myeloablative chemotherapy for solid tumors, the administration of PEG-rHuMGDF following chemotherapy for acute leukemia has failed to produce enhancement of platelet recovery when given after standard myeloablative induction regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. The reasons for this failure are not entirely clear. They may relate to the absence of sufficient marrow progenitors upon which to act, high endogenous thrombopoietin levels, or an inappropriate administration scheme. Attempts to increase the dose of thrombopoietin or alter the dosing scheme (to include doses prior to, during, or after induction or consolidation chemotherapy) did not have an effect on the platelet count [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/62\">",
"     62",
"    </a>",
"    ]. Indeed, neutropenia was actually prolonged when the thrombopoietin was given during chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9580764\">",
"    <span class=\"h2\">",
"     Hematopoietic cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although comprising a small number of patients, hematopoietic cell transplant (HCT) recipients, especially those who have delayed or absent engraftment of platelets, consume a disproportionately large amount of the national supply of platelets. Accordingly, stimulation of megakaryocyte and platelet engraftment after HCT is an important potential use of thrombopoietin. In several animal models, recombinant thrombopoietin was administered after infusion of bone marrow with no significant effect on the recovery of any hematopoietic cell lineage [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The results of administration of PEG-rHuMGDF or rHuTPO after autologous HCT in general have been disappointing, with no enhancement of platelet recovery and no reduction in platelet transfusions. Several different approaches have been tried:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report, rHuTPO was administered to patients who had received either bone marrow or peripheral blood transplants and had failed to engraft platelets after 30 days [",
"      <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/63\">",
"       63",
"      </a>",
"      ]. Only 3 of 37 patients showed increased bone marrow megakaryocytes, and only two became transfusion-independent.",
"     </li>",
"     <li>",
"      A second study evaluated patients with breast cancer undergoing autologous HCT using bone marrow stem cells (STAMP V regimen) who were given PEG-rHuMGDF immediately after the stem cell infusion [",
"      <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/30\">",
"       30",
"      </a>",
"      ]. There was no effect on the number of days that the patients had severe thrombocytopenia (ie, a platelet count",
"      <span class=\"nowrap\">",
"       &lt;20,000/microL)",
"      </span>",
"      or on the time to platelet recovery. However, there was a dose-dependent rebound in the post-transplant platelet count.",
"     </li>",
"     <li>",
"      In another series of patients with breast cancer treated with the STAMP I regimen, PEG-rHuMGDF was given before (days -14 to -8) HCT using peripheral blood stem cell infusion and, in some patients, after the infusion as well [",
"      <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/64\">",
"       64",
"      </a>",
"      ]. The PEG-rHuMGDF treatment increased the platelet count on the day of hematopoietic stem cell infusion (228,000 versus",
"      <span class=\"nowrap\">",
"       107,000/microL)",
"      </span>",
"      but had no effect on platelet recovery or the need for platelet transfusion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9580771\">",
"    <span class=\"h3\">",
"     Stem cell mobilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;In mice, TPO administration improved stem cell harvests and subsequent engraftment. When donor animals were treated with recombinant thrombopoietin and the thrombopoietin-stimulated marrow then transplanted into recipient animals, there was a reduction in the duration of thrombocytopenia as well as earlier recovery of erythrocytes (",
"    <a class=\"graphic graphic_figure graphicRef50458 \" href=\"UTD.htm?31/6/31855\">",
"     figure 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In oncology patients, administration of thrombopoietin after infusion of stem cells had no effect. However, it does efficiently mobilize peripheral blood progenitor cells. When combined with chemotherapy and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     filgrastim",
"    </a>",
"    (G-CSF), PEG-rHuMGDF produced a 250-fold increase in the number of circulating megakaryocyte colony forming cells (Meg-CFC), a 190-fold increase in granulocyte- macrophage-CFC, a 65-fold increase in erythroid burst forming cells and a 24-fold increase in CD34+ cells when compared with patients receiving only chemotherapy and filgrastim (",
"    <a class=\"graphic graphic_figure graphicRef61207 \" href=\"UTD.htm?42/41/43677\">",
"     figure 9",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link&amp;anchor=H9#H9\">",
"     \"Sources of hematopoietic stem cells\", section on 'Hematopoietic stem cell mobilization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The utility of simultaneous G-CSF (5",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    SQ or IV twice daily on days three to eight) and rHuTPO (total dose 0.6 to 2.4",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    IV) for peripheral blood stem cell mobilization was studied in 29 breast cancer patients; a concurrent group of 20 patients receiving G-CSF only served as controls [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/31\">",
"     31",
"    </a>",
"    ]. CD34+ cell yields in the first apheresis (day six) were 4.1 and 0.8 x 10",
"    <sup>",
"     6",
"    </sup>",
"    <span class=\"nowrap\">",
"     cells/kg",
"    </span>",
"    for the",
"    <span class=\"nowrap\">",
"     G-CSF/TPO",
"    </span>",
"    and G-CSF groups, respectively. The targeted minimum yield of 3 x 10",
"    <sup>",
"     6",
"    </sup>",
"    CD34+",
"    <span class=\"nowrap\">",
"     cells/kg",
"    </span>",
"    was procured following a single apheresis in 61 and 10 percent of subjects in the",
"    <span class=\"nowrap\">",
"     G-CSF/TPO",
"    </span>",
"    and G-CSF groups, respectively. Use of TPO with G-CSF modestly accelerated platelet and granulocyte recovery post-chemotherapy and modestly reduced RBC transfusion requirements; no adverse toxicities were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ultimate role of thrombopoietin in HCT may be to stimulate the number of progenitor cells in the marrow or peripheral stem cell population prior to harvesting. As suggested by murine models [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/65\">",
"     65",
"    </a>",
"    ], it may be more important to use thrombopoietin to treat the stem cell",
"    <strong>",
"     donor",
"    </strong>",
"    rather than the recipient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac surgery, liver transplantation, or other major surgery consume about 40 percent of all platelets transfused in North America, a need that might be ameliorated by thrombopoietin administration. Although no clinical studies have been undertaken, in an animal model of cardiac surgery, precisely timed administration of PEG-rHuMGDF prior to cardiac bypass reduced bleeding, improved platelet function, and reduced thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the approximately five-day lead time it takes for thrombopoietin to increase platelet production [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/5\">",
"     5",
"    </a>",
"    ], this animal study suggests that precise timing of thrombopoietin treatment prior to cardiac surgery or other major surgery may be beneficial. However, there remains the concern that the administration of thrombopoietin to patients with ongoing arterial clotting, with resulting thrombocytosis, might exacerbate their disease (see",
"    <a class=\"local\" href=\"#H34\">",
"     'Thrombocytosis and thrombosis'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Nonetheless, some chronically thrombocytopenic (platelet counts",
"    <span class=\"nowrap\">",
"     &lt;50,000/microL)",
"    </span>",
"    patients might benefit from brief treatment with a TPO receptor agonist to elevate the platelet count prior to major surgical procedures. This author has used brief courses of TPO receptor agonists to increase the platelet count in a number of patients who otherwise would not be able to undergo hip arthroplasty, CABG, or heart transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     TRANSFUSION MEDICINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to its regulatory role in platelet production, thrombopoietin also has an important physiologic role in the regulation of early hematopoiesis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. As a result, there are potential applications for the use of thrombopoietin in stem cell mobilization and expansion as well as stimulation of platelet production ex vivo and in vivo.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Ex vivo expansion of progenitor cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombopoietin in combination with other hematopoietic growth factors (eg, flt-3 ligand, IL-3) may be used to expand cord blood or peripheral blood progenitor cells ex vivo. In one study, for example, a simple cocktail of flt-3 ligand and thrombopoietin expanded cord blood progenitors several hundred thousand-fold after 25 weeks in culture (",
"    <a class=\"graphic graphic_figure graphicRef57003 \" href=\"UTD.htm?21/5/21584\">",
"     figure 10",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/69\">",
"     69",
"    </a>",
"    ]. These expanded progenitor populations appear to provide adequate hematopoietic reconstitution in mice [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Ex vivo platelet production",
"    </span>",
"    &nbsp;&mdash;&nbsp;Platelets can be produced in vitro under the stimulation of thrombopoietin. Although probably not an economical source of platelets, CD34+ cells can be grown in the presence of thrombopoietin such that most of the cells become megakaryocytes and, in turn, shed platelets [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/71\">",
"     71",
"    </a>",
"    ]. These shed platelets have normal ultrastructure and function compared with their in vivo counterparts [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Increasing platelet apheresis yields",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombopoietin stimulates platelet production in normal apheresis donors and increases the apheresis yield. As an example, treatment of apheresis donors with a single dose of PEG-rHuMGDF on day 1 produced a dose-dependent rise in the platelet count that peaked after 12 to 15 days [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/73\">",
"     73",
"    </a>",
"    ]. Compared with placebo-treated donors who had platelet counts of",
"    <span class=\"nowrap\">",
"     248,000/microL,",
"    </span>",
"    donors treated with 1 or 3",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    of PEG-rHuMGDF had median platelet counts of 366,000 and",
"    <span class=\"nowrap\">",
"     602,000/microL,",
"    </span>",
"    respectively. There was a direct relationship between the platelet count and the yield at apheresis: 3.8 x 10",
"    <sup>",
"     11",
"    </sup>",
"    platelets in placebo treated donors compared with 5.6 and 11 x 10",
"    <sup>",
"     11",
"    </sup>",
"    platelets in the 1 and 3",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    treated donors, respectively (",
"    <a class=\"graphic graphic_figure graphicRef66293 \" href=\"UTD.htm?43/17/44318\">",
"     figure 11",
"    </a>",
"    ). The administration of PEG-rHuMGDF had no adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The PEG-rHuMGDF-treated apheresis product had normal platelet aggregation responses in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/73\">",
"     73",
"    </a>",
"    ], and when transfused into thrombocytopenic recipients, produced a dose-dependent rise in platelet count of 19,000, 41,000, and",
"    <span class=\"nowrap\">",
"     82,000/microL",
"    </span>",
"    for the platelets obtained from donors treated with placebo, 1, or 3",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    PEG-rHuMGDF, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/74\">",
"     74",
"    </a>",
"    ]. There was a statistically significant increase in the time to the next prophylactic platelet transfusion for both of the PEG-rHuMGDF platelet products, compared with the placebo product (2.6, 3.8, and 1.7 days, respectively). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/31/26106?source=see_link&amp;anchor=H19#H19\">",
"     \"Procedures used for blood donor screening: Protection of potential blood donors and recipients\", section on 'Stimulation of thrombopoiesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     IMPACT ON PLATELET TRANSFUSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There was much early enthusiasm for using thrombopoietin in the acute treatment of thrombocytopenia in lieu of platelet transfusions [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/75\">",
"     75",
"    </a>",
"    ]. However, since none of the thrombopoietic molecules hastens megakaryocyte fragmentation into platelets and all take five days to start to increase platelet production [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/5\">",
"     5",
"    </a>",
"    ], thrombopoietin will not replace platelet transfusions in this acute setting. Nevertheless, there remains interest in developing another substance (eg, SDF-1) that might stimulate platelet shedding from existing megakaryocytes and possibly reduce the need for acute platelet transfusions.",
"   </p>",
"   <p>",
"    It is unlikely that TPO receptor agonists will have a major impact on the need for platelet transfusions. The TPO receptor agonists may be useful in modestly reducing the incidence of thrombocytopenia in nonmyeloablative chemotherapy. However, since this type of thrombocytopenia is a rather uncommon event in routine oncology practice, there will probably be little reduction in the overall use of platelet transfusions. For several newer chemotherapy regimens (eg, use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    ) in which thrombocytopenia is more marked, thrombopoietic growth factors may be of greater, as yet untested, use.",
"   </p>",
"   <p>",
"    Based on prior studies with the recombinant thrombopoietins, it is unlikely that the TPO receptor agonists will be of benefit in myeloablative chemotherapy or hematopoietic cell transplantation, which account for much of the platelet use in the treatment of malignant disease. However, the unique mechanism of action of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/17/11543?source=see_link\">",
"     eltrombopag",
"    </a>",
"    and its ability to potentiate the effect of TPO give some enthusiasm for studies with eltrombopag in this area.",
"   </p>",
"   <p>",
"    Rather, the major use of the thrombopoietins will probably be in treating chronic thrombocytopenic states and in enhancing the production of stem cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SIDE EFFECTS AND RISKS",
"    </span>",
"    &nbsp;&mdash;&nbsp;For any new hematopoietic growth factor, potential adverse effects must be carefully assessed. For the thrombopoietins a number of actual or potential toxicities have been identified (",
"    <a class=\"graphic graphic_table graphicRef74625 \" href=\"UTD.htm?5/44/5835\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Antibody formation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Formation of antibodies to recombinant human hematopoietic growth factors (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    , erythropoietin) has been relatively uncommon, but was a significant problem in the clinical development of the recombinant thrombopoietins. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/4/8265?source=see_link\">",
"     \"Pure red cell aplasia due to anti-erythropoietin antibodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one report, approximately 8 percent of normal volunteers developed thrombocytopenia after receiving three monthly injections of PEG-rHuMGDF. This was apparently due to the development of antibodies that cross-reacted with endogenous thrombopoietin, neutralized its biologic activity, and produced thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/76\">",
"     76",
"    </a>",
"    ]. Platelet counts as low as",
"    <span class=\"nowrap\">",
"     4000/microL",
"    </span>",
"    were reported [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/76,77\">",
"     76,77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All patients eventually recovered once the antibody abated, but clinical development of PEG-rHuMGDF by Amgen was stopped in 1998 because of this side effect. In comparison, administration of rHuTPO was not associated with neutralizing antibodies, but this agent is also no longer being developed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/31/26106?source=see_link&amp;anchor=H19#H19\">",
"     \"Procedures used for blood donor screening: Protection of potential blood donors and recipients\", section on 'Stimulation of thrombopoiesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While two subjects treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/58/20389?source=see_link\">",
"     romiplostim",
"    </a>",
"    in early clinical studies developed neutralizing antibodies against romiplostim, the antibodies were short-lived and did not cross-react with endogenous TPO. Interestingly, no subject developed antibody in subsequent clinical trials and none has been reported so far after several years of clinical use. No antibodies are expected to form against the TPO non-peptide receptor agonists.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Thrombocytosis and thrombosis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H558386901\">",
"    <span class=\"h3\">",
"     Portal vein thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/17/11543?source=see_link\">",
"     Eltrombopag",
"    </a>",
"    may be associated with a risk of thrombosis in the portal venous system in patients with advanced liver disease. One randomized trial (292 patients) of eltrombopag versus placebo in patients with chronic liver disease or cirrhosis from all causes undergoing elective invasive procedures showed an increase in thrombotic events (seven in the eltrombopag group versus three in the placebo group; odds ratio [OR]: 3.04, 95% CI 0.62-14.82) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/48\">",
"     48",
"    </a>",
"    ]. Five of six patients with thrombosis had platelet counts over",
"    <span class=\"nowrap\">",
"     200,000/microL.",
"    </span>",
"    It is unclear whether these asymptomatic portal vein thromboses were due to the eltrombopag or the underlying liver disease, as imaging studies were not performed pretreatment to assess for thrombosis that were already present at the time of eltrombopag treatment. In the much larger group of patients with HCV hepatitis treated with eltrombopag, there was no increased rate of thrombotic events, although portal vein imaging was not routinely performed [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, in blinded controlled ITP studies, subjects treated with TPO receptor agonists had the same rate of thrombosis as those treated with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/12,23\">",
"     12,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H558386935\">",
"    <span class=\"h3\">",
"     Potential mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two potential prothrombotic mechanisms of the thrombopoietin receptor agonists that deserve attention:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      These molecules can be extremely potent growth factors and can markedly elevate the platelet count in a short period of time. In a baboon model, the deposition of platelets in an extravascular shunt, which mimics an ulcerated atheroma in humans, was directly related to the platelet count after PEG-rHuMGDF administration [",
"      <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/78,79\">",
"       78,79",
"      </a>",
"      ]. Except for its ability to elevate the platelet count, PEG-rHuMGDF did not synergize with or exacerbate platelet deposition. Nevertheless, increasing the platelet count in individuals with active arterial thrombotic disease may increase the risk of thrombosis.",
"     </li>",
"     <li>",
"      Platelets produced by stimulation with any of the thrombopoietins have normal aggregation responses. However, when the recombinant thrombopoietins or peptide TPO receptor agonists (but not the non-peptide TPO receptor agonists) are added directly to platelets (or persist at elevated levels in the circulation in vivo), they decrease by approximately 50 percent the threshold for activation by various platelet agonists (eg, ADP, collagen) in platelet aggregometry studies [",
"      <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/78,79\">",
"       78,79",
"      </a>",
"      ]. This is probably not clinically relevant since studies with recombinant thrombopoietins in oncology patients, a patient group with an inherent increased rate of thrombosis, showed no increased rate of thrombosis. Furthermore, treatment of baboons with PEG-rHuMGDF did not increase fibrin deposition in extravascular shunts despite marked increases in platelet count [",
"      <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/78,79\">",
"       78,79",
"      </a>",
"      ]. Finally, in the rabbit carotid artery model, PEG-rHuMGDF did not alter \"cyclic flow reduction\", a sensitive test of platelet-dependent thrombosis [",
"      <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/80\">",
"       80",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Bone marrow fibrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In several preclinical models, murine bone marrow was transfected with the thrombopoietin gene, causing thrombopoietin to be expressed at very high levels in the bone marrow of mice following transplantation. Most of these mice developed extensive marrow fibrosis similar to that seen in primary myelofibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/81-83\">",
"     81-83",
"    </a>",
"    ]. This fibrotic response is probably secondary to the high local bone marrow concentrations of transforming growth factor beta1 (TGF-beta1) and other factors [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Administration of thrombopoietin to mice produces increased bone marrow reticulin, which is reversible upon discontinuation of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/85\">",
"     85",
"    </a>",
"    ]. There has been little clinical evidence for bone marrow fibrosis in humans given rhTPO or PEG-rHuMGDF. However, one case series using serial analyses of bone marrow and peripheral blood in nine patients who received rhTPO after induction therapy for acute myeloid leukemia (AML) and in eight patients undergoing the same AML induction treatment but without rhTPO treatment showed increased bone marrow cellularity in eight of the nine rhTPO-treated and five of the eight control patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/86\">",
"     86",
"    </a>",
"    ]. Eight of nine rhTPO-treated and two of six control patients had increased bone marrow reticulin staining. These morphologic findings resolved within 42 days of the last dose of rhTPO. Given the brevity of most exposures and the lack of routine bone marrow analysis, this potential issue was not fully explored.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/58/20389?source=see_link\">",
"     Romiplostim",
"    </a>",
"    causes a reversible increase in reticulin in rats [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/87\">",
"     87",
"    </a>",
"    ]. Thus far, fewer than 5 percent of ITP subjects treated with the TPO receptor agonists have been reported to have increased reticulin. In some it was present at baseline; in others it increased from pretreatment levels, and receded upon discontinuation of treatment; in others it increased and then decreased despite continued therapy. Only a rare patient exhibited signs of collagen formation in addition to reticulin [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/88\">",
"     88",
"    </a>",
"    ]. No patient developed other cytopenias or a myeloproliferative syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/87\">",
"     87",
"    </a>",
"    ]. Long-term prospective bone marrow studies are underway in ITP patients exposed to romiplostim and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/17/11543?source=see_link\">",
"     eltrombopag",
"    </a>",
"    to evaluate this issue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1731264\">",
"    <span class=\"h2\">",
"     Rebound thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A risk of TPO receptor agonists in ITP patients comes from abruptly stopping treatment. An unfortunate aspect of product labeling for TPO receptor agonists in ITP is the suggestion that they be held if the platelet count rises over 400,000; this is based on no identified risk but was part of the dosing algorithm of the initial clinical trials. Unfortunately, given the greatly shorted platelet life-span, stopping the drug results in a rapid decrease in platelet count; platelet counts may often drop from &gt;400,000 to less than 5000 in less than one week. Rebound thrombocytopenia (defined as the platelet count dropping 10,000 below the prior baseline) was seen in approximately 10 percent of clinical trial patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/61/21466/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4016840\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of thrombopoietin (TPO) molecules have been developed; they define a new and growing family of molecules called the thrombopoietin (c-mpl ligand) family, based upon their common ability to bind and activate the TPO receptor, c-mpl (",
"    <a class=\"graphic graphic_table graphicRef55953 \" href=\"UTD.htm?21/44/22219\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The two TPO receptor agonists currently available for use in immune thrombocytopenia (ITP) are",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/58/20389?source=see_link\">",
"       romiplostim",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/17/11543?source=see_link\">",
"       eltrombopag",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29194?source=see_link&amp;anchor=H5#H5\">",
"       \"Chronic refractory immune (idiopathic) thrombocytopenic purpura in adults\", section on 'Thrombopoiesis-stimulating agents'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The TPO receptor agonists are currently under evaluation for a wide range of other thrombocytopenic disorders, including those associated with chemotherapy and hepatitis C. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Use of TPO receptor agonists'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Side effects of the TPO receptor agonists include antibody formation, thrombocytosis, thrombosis, bone marrow fibrosis, and rebound thrombocytopenia. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Side effects and risks'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/1\">",
"      Sheridan WP, Kuter DJ. Mechanism of action and clinical trials of Mpl ligand. Curr Opin Hematol 1997; 4:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/2\">",
"      Kuter DJ. New thrombopoietic growth factors. Clin Lymphoma Myeloma 2009; 9 Suppl 3:S347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/3\">",
"      Kuter DJ. New thrombopoietic growth factors. Blood 2007; 109:4607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/4\">",
"      Kuter DJ. Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia. Annu Rev Med 2009; 60:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/5\">",
"      Vadhan-Raj S, Murray LJ, Bueso-Ramos C, et al. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med 1997; 126:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/6\">",
"      Basser RL, Begley CG. Thrombopoietin. Cancer Invest 2001; 19:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/7\">",
"      Cwirla SE, Balasubramanian P, Duffin DJ, et al. Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science 1997; 276:1696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/8\">",
"      Molineux G. The development of romiplostim for patients with immune thrombocytopenia. Ann N Y Acad Sci 2011; 1222:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/9\">",
"      Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 2004; 76:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/10\">",
"      Broudy VC, Lin NL. AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. Cytokine 2004; 25:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/11\">",
"      Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 2006; 355:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/12\">",
"      Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008; 371:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/13\">",
"      Kuter DJ, Rummel M, Boccia R, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med 2010; 363:1889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/14\">",
"      Sekeres MA, Kantarjian H, Fenaux P, et al. Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. Cancer 2011; 117:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/15\">",
"      Kantarjian H, Fenaux P, Sekeres MA, et al. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol 2010; 28:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/16\">",
"      Kantarjian HM, Giles FJ, Greenberg PL, et al. Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood 2010; 116:3163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/17\">",
"      Duffy KJ, Shaw AN, Delorme E, et al. Identification of a pharmacophore for thrombopoietic activity of small, non-peptidyl molecules. 1. Discovery and optimization of salicylaldehyde thiosemicarbazone thrombopoietin mimics. J Med Chem 2002; 45:3573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/18\">",
"      Duffy KJ, Darcy MG, Delorme E, et al. Hydrazinonaphthalene and azonaphthalene thrombopoietin mimics are nonpeptidyl promoters of megakaryocytopoiesis. J Med Chem 2001; 44:3730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/19\">",
"      Duffy KJ, Price AT, Delorme E, et al. Identification of a pharmacophore for thrombopoietic activity of small, non-peptidyl molecules. 2. Rational design of naphtho[1,2-d]imidazole thrombopoietin mimics. J Med Chem 2002; 45:3576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/20\">",
"      Erickson-Miller CL, DeLorme E, Tian SS, et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol 2005; 33:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/21\">",
"      Jenkins JM, Williams D, Deng Y, et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 2007; 109:4739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/22\">",
"      Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 373:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/23\">",
"      Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 2011; 377:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/24\">",
"      Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007; 357:2237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/25\">",
"      McHutchison JG, Dusheiko G, Shiffman ML, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007; 357:2227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/26\">",
"      Fukushima-Shintani M, Suzuki K, Iwatsuki Y, et al. AKR-501 (YM477) in combination with thrombopoietin enhances human megakaryocytopoiesis. Exp Hematol 2008; 36:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/27\">",
"      Fukushima-Shintani M, Suzuki K, Iwatsuki Y, et al. AKR-501 (YM477) a novel orally-active thrombopoietin receptor agonist. Eur J Haematol 2009; 82:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/28\">",
"      Desjardins RE, Tempel DL, Lucek R, Kuter DJ. Single and multiple oral doses of AKR-501 (TM477) increase the platelet count in healthy volunteers (abstract). Blood 2006; 108:145a.",
"     </a>",
"    </li>",
"    <li>",
"     Kaye JA. FDA Licensure of NEUMEGA to prevent severe chemotherapy-induced thrombocytopenia. In: Thrombopoietin: From Molecule to Medicine, Murphy MJ, Kuter DJ (Eds), AlphaMed Press, Miamisburg 1998. p.207.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/30\">",
"      Schuster MW, Beveridge R, Frei-Lahr D, et al. The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation. Exp Hematol 2002; 30:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/31\">",
"      Somlo G, Sniecinski I, ter Veer A, et al. Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy. Blood 1999; 93:2798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/32\">",
"      Kizaki M, Miyakawa Y, Ikeda Y. Long-term administration of pegylated recombinant human megakaryocyte growth and development factor dramatically improved cytopenias in a patient with myelodysplastic syndrome. Br J Haematol 2003; 122:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/33\">",
"      McMillan R, Wang L, Tomer A, et al. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood 2004; 103:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/34\">",
"      Tsimberidou AM, Giles FJ, Khouri I, et al. Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience. Ann Oncol 2005; 16:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/35\">",
"      Aribi A, Kantarjian H, Koller C, et al. The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer 2008; 113:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/36\">",
"      Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 2002; 100:3457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/37\">",
"      Nichol JL. Thrombopoietin levels after chemotherapy and in naturally occurring human diseases. Curr Opin Hematol 1998; 5:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/38\">",
"      Emmons RV, Reid DM, Cohen RL, et al. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood 1996; 87:4068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/39\">",
"      Ballem PJ, Segal GM, Stratton JR, et al. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance. J Clin Invest 1987; 80:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/40\">",
"      Rice L, Nichol JL, McMillan R, et al. Cyclic immune thrombocytopenia responsive to thrombopoietic growth factor therapy. Am J Hematol 2001; 68:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/41\">",
"      Nomura S, Dan K, Hotta T, et al. Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura. Blood 2002; 100:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/42\">",
"      Kuter DJ, Bussel J, Newland A, et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenic purpura (ITP): 3-year update from an open-label extension study. Blood 2008; 112:154a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/43\">",
"      Will B, Kawahara M, Luciano JP, et al. Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. Blood 2009; 114:3899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/44\">",
"      Komatsu N, Okamoto T, Yoshida T, et al. Pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) increased platelet counts (plt) in patients with aplastic anemia (AA) and myelodysplastic syndrome (MDS) (abstract). Blood 2000; 96:296a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/45\">",
"      Harker LA, Carter RA, Marzec UM, et al. Correction of thrombocytopenia and ineffective platelet production in patients infected with human immunodeficiency virus (HIV) by PEG-rHuMGDF therapy (abstract). Blood 1998; 92:707a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/46\">",
"      Martin TG 3rd, Somberg KA, Meng YG, et al. Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation. Ann Intern Med 1997; 127:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/47\">",
"      Peck-Radosavljevic M, Wichlas M, Zacherl J, et al. Thrombopoietin induces rapid resolution of thrombocytopenia after orthotopic liver transplantation through increased platelet production. Blood 2000; 95:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/48\">",
"      Afdhal NH, Giannini EG, Tayyab G, et al. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med 2012; 367:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/49\">",
"      Ballmaier M, Schulze H, Strauss G, et al. Thrombopoietin in patients with congenital thrombocytopenia and absent radii: elevated serum levels, normal receptor expression, but defective reactivity to thrombopoietin. Blood 1997; 90:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/50\">",
"      Ballmaier M, Germeshausen M, Schulze H, et al. c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. Blood 2001; 97:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/51\">",
"      van den Oudenrijn S, Bruin M, Folman CC, et al. Mutations in the thrombopoietin receptor, Mpl, in children with congenital amegakaryocytic thrombocytopenia. Br J Haematol 2000; 110:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/52\">",
"      Orita T, Tsunoda H, Yabuta N, et al. A novel therapeutic approach for thrombocytopenia by minibody agonist of the thrombopoietin receptor. Blood 2005; 105:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/53\">",
"      Balduini CL, Pecci A, Savoia A. Recent advances in the understanding and management of MYH9-related inherited thrombocytopenias. Br J Haematol 2011; 154:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/54\">",
"      Pecci A, Gresele P, Klersy C, et al. Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations. Blood 2010; 116:5832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/55\">",
"      Hokom MM, Lacey D, Kinstler OB, et al. Pegylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice. Blood 1995; 86:4486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/56\">",
"      Fanucchi M, Glaspy J, Crawford J, et al. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med 1997; 336:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/57\">",
"      Basser RL, Rasko JE, Clarke K, et al. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood 1997; 89:3118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/58\">",
"      Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C, et al. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med 2000; 132:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/59\">",
"      Moskowitz CH, Hamlin PA, Gabrilove J, et al. Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma. Ann Oncol 2007; 18:1842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/60\">",
"      Schiffer CA, Miller K, Larson RA, et al. A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood 2000; 95:2530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/61\">",
"      Archimbaud E, Ottmann OG, Yin JA, et al. A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia. Blood 1999; 94:3694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/62\">",
"      Geissler K, Yin JA, Ganser A, et al. Prior and concurrent administration of recombinant human megakaryocyte growth and development factor in patients receiving consolidation chemotherapy for de novo acute myeloid leukemia--a randomized, placebo-controlled, double-blind safety and efficacy study. Ann Hematol 2003; 82:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/63\">",
"      Nash R, Kurzrock R, DiPersio J, et al. Safety and activity of recombinant human thrombopoietin (rhTPO) in patients (pts) with delayed platelet recovery (DPR) (abstract). Blood 1997; 90:262a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/64\">",
"      Glaspy J, Vredenburgh J, Demetri GD, et al. Effects of PEGylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) before high dose chemotherapy (HDC) with peripheral blood progenitor cell (PBPC) support (abstract). Blood 1997; 90:580a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/65\">",
"      Fibbe WE, Heemskerk DP, Laterveer L, et al. Accelerated reconstitution of platelets and erythrocytes after syngeneic transplantation of bone marrow cells derived from thrombopoietin pretreated donor mice. Blood 1995; 86:3308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/66\">",
"      Nakamura M, Toombs CF, Duarte IG, et al. Recombinant human megakaryocyte growth and development factor attenuates postbypass thrombocytopenia. Ann Thorac Surg 1998; 66:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/67\">",
"      Kaushansky K. Thrombopoietin and the hematopoietic stem cell. Blood 1998; 92:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/68\">",
"      Solar GP, Kerr WG, Zeigler FC, et al. Role of c-mpl in early hematopoiesis. Blood 1998; 92:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/69\">",
"      Piacibello W, Sanavio F, Garetto L, et al. Extensive amplification and self-renewal of human primitive hematopoietic stem cells from cord blood. Blood 1997; 89:2644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/70\">",
"      Yagi M, Ritchie KA, Sitnicka E, et al. Sustained ex vivo expansion of hematopoietic stem cells mediated by thrombopoietin. Proc Natl Acad Sci U S A 1999; 96:8126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/71\">",
"      Thon JN, Italiano JE. Platelet formation. Semin Hematol 2010; 47:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/72\">",
"      Choi ES, Nichol JL, Hokom MM, et al. Platelets generated in vitro from proplatelet-displaying human megakaryocytes are functional. Blood 1995; 85:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/73\">",
"      Kuter DJ, Goodnough LT, Romo J, et al. Thrombopoietin therapy increases platelet yields in healthy platelet donors. Blood 2001; 98:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/74\">",
"      Goodnough LT, Kuter DJ, McCullough J, et al. Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin. Blood 2001; 98:1346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/75\">",
"      Kuter DJ. Thrombopoietin: biology, clinical applications, role in the donor setting. J Clin Apher 1996; 11:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/76\">",
"      Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001; 98:3241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/77\">",
"      Basser RL, O'Flaherty E, Green M, et al. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood 2002; 99:2599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/78\">",
"      Harker LA, Marzec UM, Hunt P, et al. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates. Blood 1996; 88:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/79\">",
"      Harker LA, Hunt P, Marzec UM, et al. Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates. Blood 1996; 87:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/80\">",
"      Harker LA. Platelets in thrombotic disorders: quantitative and qualitative platelet disorders predisposing to arterial thrombosis. Semin Hematol 1998; 35:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/81\">",
"      Yan XQ, Lacey D, Fletcher F, et al. Chronic exposure to retroviral vector encoded MGDF (mpl-ligand) induces lineage-specific growth and differentiation of megakaryocytes in mice. Blood 1995; 86:4025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/82\">",
"      Frey BM, Rafii S, Teterson M, et al. Adenovector-mediated expression of human thrombopoietin cDNA in immune-compromised mice: insights into the pathophysiology of osteomyelofibrosis. J Immunol 1998; 160:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/83\">",
"      Villeval JL, Cohen-Solal K, Tulliez M, et al. High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. Blood 1997; 90:4369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/84\">",
"      Yanagida M, Ide Y, Imai A, et al. The role of transforming growth factor-beta in PEG-rHuMGDF-induced reversible myelofibrosis in rats. Br J Haematol 1997; 99:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/85\">",
"      Ulich TR, del Castillo J, Senaldi G, et al. Systemic hematologic effects of PEG-rHuMGDF-induced megakaryocyte hyperplasia in mice. Blood 1996; 87:5006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/86\">",
"      Douglas VK, Tallman MS, Cripe LD, Peterson LC. Thrombopoietin administered during induction chemotherapy to patients with acute myeloid leukemia induces transient morphologic changes that may resemble chronic myeloproliferative disorders. Am J Clin Pathol 2002; 117:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/87\">",
"      Kuter DJ, Mufti GJ, Bain BJ, et al. Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. Blood 2009; 114:3748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/61/21466/abstract/88\">",
"      Kuter DJ, Bain B, Mufti G, et al. Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. Br J Haematol 2007; 139:351.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6671 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.18-37D25D05A2-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_61_21466=[""].join("\n");
var outline_f20_61_21466=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4016840\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6974285\">",
"      CLINICAL UTILITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      THROMBOPOIETINS (C-MPL LIGANDS)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Recombinant thrombopoietins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Peptide thrombopoietin receptor agonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Romiplostim (AMG 531, Nplate)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Non-peptide TPO receptor agonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Eltrombopag (SB497115, Promacta/Revolade)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - E5501 (formerly AKR-501 and YM 477)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      OTHER THROMBOPOIETIC GROWTH FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Interleukins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Oprelvekin (IL-11, Neumega)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      USE OF TPO RECEPTOR AGONISTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6974564\">",
"      Immune thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Myelodysplastic syndromes and aplastic anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      HIV-associated thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Liver disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H558386947\">",
"      - Rationale",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Chronic HCV infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H558387015\">",
"      - Advanced liver disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Thrombocytopenia with absent radius syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Congenital amegakaryocytic thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1731175\">",
"      MYH9-related congenital thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9580690\">",
"      OTHER POTENTIAL USES OF TPO RECEPTOR AGONISTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9580743\">",
"      Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9580750\">",
"      - Solid tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9580757\">",
"      - Acute leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9580764\">",
"      Hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9580771\">",
"      - Stem cell mobilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      TRANSFUSION MEDICINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Ex vivo expansion of progenitor cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Ex vivo platelet production",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Increasing platelet apheresis yields",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      IMPACT ON PLATELET TRANSFUSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SIDE EFFECTS AND RISKS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Antibody formation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Thrombocytosis and thrombosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H558386901\">",
"      - Portal vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H558386935\">",
"      - Potential mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Bone marrow fibrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1731264\">",
"      Rebound thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4016840\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/6671\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6671|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/13/5343\" title=\"figure 1\">",
"      Use of platelet transfusions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/48/783\" title=\"figure 2\">",
"      Structure recombinant TPO",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/62/5103\" title=\"figure 3\">",
"      Structure AMG 531",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/8/19584\" title=\"figure 4\">",
"      Structure eltrombopag",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/17/32030\" title=\"figure 5\">",
"      PEG rHuMGDF in myelosuppression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/0/2062\" title=\"figure 6\">",
"      PEG rHuMGDF after chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/52/8014\" title=\"figure 7\">",
"      rHuTPO intensive chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/6/31855\" title=\"figure 8\">",
"      rTPO to transplant donor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/41/43677\" title=\"figure 9\">",
"      PEG rHuMGDF PBPC mobilization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/5/21584\" title=\"figure 10\">",
"      TPO and cord blood progenitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/17/44318\" title=\"figure 11\">",
"      Pheresis yield PEG rHuMGDF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6671|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/44/22219\" title=\"table 1\">",
"      Thrombopoietic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/54/20331\" title=\"table 2\">",
"      Romiplostim in chronic ITP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/44/5835\" title=\"table 3\">",
"      Risks platelet stim factors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16680?source=related_link\">",
"      Biology and physiology of thrombopoietin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29194?source=related_link\">",
"      Chronic refractory immune (idiopathic) thrombocytopenic purpura in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20586?source=related_link\">",
"      Clinical and laboratory aspects of platelet transfusion therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33914?source=related_link\">",
"      Coagulation abnormalities in patients with liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/9/29850?source=related_link\">",
"      Congenital and acquired disorders of platelet function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14522?source=related_link\">",
"      Hematologic manifestations of HIV infection: Thrombocytopenia and coagulation abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/31/16890?source=related_link\">",
"      Introduction to recombinant hematopoietic growth factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/54/25450?source=related_link\">",
"      Management of the complications of the myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14490?source=related_link\">",
"      Neonatal thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/31/26106?source=related_link\">",
"      Procedures used for blood donor screening: Protection of potential blood donors and recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/4/8265?source=related_link\">",
"      Pure red cell aplasia due to anti-erythropoietin antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=related_link\">",
"      Sources of hematopoietic stem cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39322?source=related_link\">",
"      Treatment and prognosis of immune (idiopathic) thrombocytopenic purpura in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_61_21467="Hints early Dx FM";
var content_f20_61_21467=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F63893&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F63893&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Hints for early and cost-effective diagnosis of fibromyalgia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Chronic widespread musculoskeletal pain for &ge;3 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Absence of other systemic condition accounting for pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Excess tenderness in soft-tissues",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Characteristic symptoms:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; \"I hurt all over\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; \"It feels like I always have the flu\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Fatigue, sleep and mood disturbances",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; IBS, irritable bladder, multiple other somatic complaints",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Exclusion of structural or systemic disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Not a \"fishing\" expedition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Avoid \"screening\" rheumatology tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Most efficient with early subspecialty referral",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Don L Goldenberg, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_61_21467=[""].join("\n");
var outline_f20_61_21467=null;
var title_f20_61_21468="DMPA injection";
var content_f20_61_21468=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F69414&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F69414&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Timing of first injection and subsequent injections of DMPA",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Method",
"       </td>",
"       <td class=\"subtitle1\">",
"        DMPA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        First injection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Spontaneous menstrual cycle",
"       </td>",
"       <td>",
"        Within seven days of menses onset",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Spontaneous or induced first-trimester abortion",
"       </td>",
"       <td>",
"        Within seven days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Term delivery",
"       </td>",
"       <td>",
"        Within three weeks postpartum if not breastfeeding; at least four to six weeks postpartum if breastfeeding*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Switching from combination OCs",
"       </td>",
"       <td>",
"        While on active pills or within seven days after taking the pill pack's last active tablet",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Switching from combination contraceptive patch (Ortho Evra&reg;)",
"       </td>",
"       <td>",
"        While on weekly patch or within seven days after patch removal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Switching from combination contraceptive vaginal ring (NuvaRing&reg;)",
"       </td>",
"       <td>",
"        While ring is in place or within seven days after ring removal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Switching from levonorgestrel IUD (Mirena&reg;)",
"       </td>",
"       <td>",
"        First injection should occur before IUD removal and within five years after IUD insertion; if patient is menstruating, a condom should be used as back-up if the first injection is not given within seven days of menses onset",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Switching from Copper T 380A IUD",
"       </td>",
"       <td>",
"        First injection should occur before IUD removal and within 10 years after IUD insertion; a condom should be used as a back-up if the first injection is not given within five days of menses onset",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Subsequent injections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Injection interval",
"       </td>",
"       <td>",
"        Every 12 weeks or three months; earlier reinjections are acceptable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Grace period",
"       </td>",
"       <td>",
"        Two weeks; after one week the manufacturer recommends pregnancy testing before repeat injection",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     DMPA: depot medroxyprogesterone acetate; OCs: oral contraceptives.",
"     <br>",
"      * WHO suggests waiting at least six weeks, CDC suggests waiting at least 4 weeks.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_61_21468=[""].join("\n");
var outline_f20_61_21468=null;
var title_f20_61_21469="DT DTaP contraindications";
var content_f20_61_21469=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63855&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63855&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Contraindications and precautions to diphtheria, tetanus, and pertussis vaccines for children aged 0 through 6 years",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Vaccine",
"       </td>",
"       <td class=\"subtitle1\">",
"        Contraindications",
"       </td>",
"       <td class=\"subtitle1\">",
"        Precautions*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Neither contraindications nor precautions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        DTaP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"7\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        Severe allergic reaction (eg, anaphylaxis) after a previous vaccine dose or to a vaccine component",
"       </td>",
"       <td>",
"        Moderate or severe acute illness with or without fever",
"       </td>",
"       <td>",
"        Mild acute illness with or without fever",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Encephalopathy (eg, coma, decreased level of consciousness, prolonged seizures) not attributable to another identifiable cause within 7 days of administration of DTwP/DTaP",
"       </td>",
"       <td>",
"        Temperature &ge;105&deg;F (40.5&deg;C) for 48 hours after vaccination with a previous dose of DTwP/DTaP",
"       </td>",
"       <td>",
"        Family history of seizure or sudden infant death syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Progressive neurologic disorder, including infantile spasms, uncontrolled epilepsy, progressive encephalopathy: defer DTaP until neurologic status clarified and stabilized",
"       </td>",
"       <td>",
"        Collapse or shock-like state (ie, hypotonic hyporesponsive episode) within 48 hours after DTwP/DTaP",
"       </td>",
"       <td>",
"        Stable or resolved neurologic condition (eg, controlled idiopathic epilepsy, cerebral palsy, developmental delay)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Seizure within 3 days after DTwP/DTaP",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Immunosuppression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Persistent inconsolable crying lasting &ge;3 hours within 48 hours after DTwP/DTaP",
"       </td>",
"       <td>",
"        Extensive local reaction to fourth DTaP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Guillain-Barr&eacute; syndrome within 6 weeks of tetanus toxoid-containing vaccine",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        History of Arthus-type hypersensitivity reaction following diphtheria- or tetanus toxoid-containing vaccine (including MCV4)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        DT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        Severe allergic reaction (eg, anaphylaxis) after a previous vaccine dose or to a vaccine component",
"       </td>",
"       <td>",
"        Moderate or severe acute illness with or without fever",
"       </td>",
"       <td>",
"        (As for DTaP)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Guillain-Barr&eacute; syndrome within 6 weeks after tetanus toxoid-containing vaccine",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        History of Arthus-type hypersensitivity reaction following diphtheria- or tetanus toxoid-containing vaccine (including MCV4)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     DTaP: diphtheria toxoid, tetanus toxoid, acellular pertussis vaccine; DTwP: diphtheria tetanus, whole-cell pertussis vaccine; DT: diphtheria toxoid, tetanus toxoid (pediatric DT); MCV4: quadrivalent meningococcal conjugate vaccine.",
"     <br>",
"      * Precautions should be reviewed carefully. Benefits and risks of administering specific vaccines to a person under these circumstances should be considered. If the risk from the vaccine is believed to outweigh the benefit, the vaccine should not be administered. Whether and when to administer DTaP to children with proven or suspected underlying disorders should be decided on a case-by-case basis.",
"      <br>",
"       &bull; Acetaminophen or other appropriate antipyretic can be administered to infants and children with a history of seizures at the time of DTaP vaccination and at appropriate intervals for 24 hours thereafter to reduce the possibility of postvaccination fever.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from:",
"     <br>",
"      1. Immunization Action Coalition. Guide to contraindications and precautions to commonly used vaccines. Available at:",
"      <a href=\"file://www.immunize.org/catg.d/p3072A.pdf\">",
"       file://www.immunize.org/catg.d/p3072A.pdf",
"      </a>",
"      . Accessed on June 23, 2012.",
"      <br>",
"       2. Kroger AT, Sumaya CV, Pickering LK, Atkinson WL. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1.",
"       <br>",
"        3. American Academy of Pediatrics. Pertussis (whooping cough). In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK. (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.553.",
"        <br>",
"         4. American Academy of Pediatrics. Vaccine contraindications and precautions In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK. (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.49.",
"         <br/>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_61_21469=[""].join("\n");
var outline_f20_61_21469=null;
var title_f20_61_21470="CIWA-Ar withdrawal scale";
var content_f20_61_21470=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F64835&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F64835&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical institute withdrawal assessment scale for alcohol, revised (CIWA-Ar)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Nausea and vomiting",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            0 No nausea or vomiting",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            2",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            3",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            4 Intermittent nausea with dry heaves",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            5",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            6",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            7 Constant nausea, frequent dry heaves and vomiting",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Paroxysmal sweats",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            0 No sweats visible",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1 Barely perceptible sweating, palms moist",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            2",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            3",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            4 Beads of sweat obvious on forehead",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            5",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            6",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            7 Drenching sweats",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Anxiety",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            0 No anxiety, at ease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            2",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            3",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            4 Moderately anxious, guarded",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            5",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            6",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            7 Acute panic state, consistent with severe delirium or acute schizophrenia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Agitation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            0 Normal activity",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1 Somewhat more than normal activity",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            2",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            3",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            4 Moderately fidgety and restless",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            5",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            6",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            7 Paces back and forth during most of the interview or constantly thrashes about",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Tremor",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            0 No tremor",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1 Not visible, but can be felt at fingertips",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            2",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            3",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            4 Moderate when patient's hands extended",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            5",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            6",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            7 Severe, even with arms not extended",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Headache",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            0 Not present",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1 Very mild",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            2 Mild",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            3 Moderate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td colspan=\"1\">",
"            4 Moderately severe",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            5 Severe",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            6 Very severe",
"           </td>",
"          </tr>",
"          <tr>",
"           <td colspan=\"1\">",
"            7 Extremely severe",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\" colspan=\"1\">",
"            Auditory disturbances",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            0 Not present",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1 Very mild harshness or ability to frighten",
"           </td>",
"          </tr>",
"          <tr>",
"           <td colspan=\"1\">",
"            2 Mild harshness or ability to frighten",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            3 Moderate harshness or ability to frighten",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            4 Moderately severe hallucinations",
"           </td>",
"          </tr>",
"          <tr>",
"           <td colspan=\"1\">",
"            5 Severe hallucinations",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            6 Extremely severe hallucinations",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            7 Continuous hallucinations",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\" colspan=\"1\">",
"            Visual disturbances",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            0 Not present",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1 Very mild photosensitivity",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            2 Mild photosensitivity",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            3 Moderate photosensitivity",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            4 Moderately severe visual hallucinations",
"           </td>",
"          </tr>",
"          <tr>",
"           <td colspan=\"1\">",
"            5 Severe visual hallucinations",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            6 Extremely severe visual hallucinations",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            7 Continuous visual hallucinations",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\" colspan=\"1\">",
"            Tactile disturbances",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            0 None",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1 Very mild paresthesias",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            2 Mild paresthesias",
"           </td>",
"          </tr>",
"          <tr>",
"           <td colspan=\"1\">",
"            3 Moderate paresthesias",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            4 Moderately severe hallucinations",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            5 Severe hallucinations",
"           </td>",
"          </tr>",
"          <tr>",
"           <td colspan=\"1\">",
"            6 Extremely severe hallucinations",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            7 Continuous hallucinations",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\" colspan=\"1\">",
"            Orientation and clouding of sensorium",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            0 Oriented and can do serial additions",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1 Cannot do serial additions",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            2 Disoriented for date by no more than 2 calendar days",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            3 Disoriented for date by more than 2 calendar days",
"           </td>",
"          </tr>",
"          <tr>",
"           <td colspan=\"1\">",
"            4 Disoriented for place and/or patient",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\" colspan=\"1\">",
"            Total score is a simple sum of each item score (maximum score is 67).",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\" colspan=\"1\">",
"            Score:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            &lt;10: Very mild withdrawal",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\" colspan=\"1\">",
"            10-15: Mild withdrawal",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\" colspan=\"1\">",
"            16-20: Modest withdrawal",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            &gt;20: Severe withdrawal",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Sullivan, JT, Skyora, K, Schneiderman, J, et al, Br J Addict 1989; 84:1353.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_61_21470=[""].join("\n");
var outline_f20_61_21470=null;
var title_f20_61_21471="MRI basal ganglia capsular infarct";
var content_f20_61_21471=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76709&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76709&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diffusion-weighted MRI of basal ganglia and capsular infarction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 290px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     Diffusion MRI (axial view) showing a right basal ganglia and capsular high intensity lesion consistent with acute infarction (arrow).",
"    </p>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_61_21471=[""].join("\n");
var outline_f20_61_21471=null;
